<SEC-DOCUMENT>0001628280-20-014029.txt : 20200930
<SEC-HEADER>0001628280-20-014029.hdr.sgml : 20200930
<ACCEPTANCE-DATETIME>20200930160036
ACCESSION NUMBER:		0001628280-20-014029
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200930
DATE AS OF CHANGE:		20200930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-232321
		FILM NUMBER:		201212260

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a093020crdf424b5.htm
<DESCRIPTION>424B5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if198fbfccf55490aa8d53f15a6567c71_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Filed Pursuant to Rule&#160;424(b)(5)</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Registration No.&#160;333-232321</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:42.346%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.123%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.231%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PROSPECTUS SUPPLEMENT  </font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;(TO PROSPECTUS DATED JULY 1, 2019)</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">                                                                       </font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:103%;">6,500,000 Shares of Common Stock</font></div><div><font><br></font></div><div style="text-align:center;"><img alt="cardiff_logoxrgbxtm2.jpg" src="cardiff_logoxrgbxtm2.jpg" style="height:38px;width:250px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:99%;">We are offering 6,500,000 shares of our common stock.  Our common stock trades on The Nasdaq Capital Market under the symbol &#8220;CRDF.&#8221; On September 28, 2020, the last reported sale price of our common stock on The Nasdaq Capital Market was $12.18 per share.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:99%;">Investing in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page S-9 of this prospectus supplement, on page 9 of the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:88%;">Neither the Securities and Exchange Commission (the &#8220;SEC&#8221;) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.543%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.420%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.714%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:2pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:2pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:2pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Per share</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Public offering price</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.50</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,750,000</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Underwriting discounts and commissions(1)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8775</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,703,750</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds, before expenses, to us</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.6225</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82,046,250</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:0.1%;"></td><td style="width:1.992%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:96.708%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">We refer you to &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">Underwriting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8221; beginning on page S-<a href="#if198fbfccf55490aa8d53f15a6567c71_34" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: none;">19</a> of this prospectus supplement for additional information regarding underwriting compensation.</font></div></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:99%;">We have granted the underwriters an option for a period of up to 30 days from the date of this prospectus supplement to purchase up to an additional 975,000 shares of our common stock.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:99%;">The underwriters expect to deliver the shares on or about October 2, 2020.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:103%;">Joint Book-Running Managers</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:47.291%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:50.509%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%;">Cowen</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%;">Piper Sandler</font></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lead Manager<br><br></font></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:88%;">H.C. Wainwright &#38; Co.</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:88%;">The date of this prospectus supplement is September 29, 2020 </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-2</font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PROSPECTUS SUPPLEMENT</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:84.133%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.667%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_7" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">About This Prospectus Supplement</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">1</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_10" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Special Note Regarding Forward-Looking Statements</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_10" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">1</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_13" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Prospectus Supplement Summary</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-3</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_16" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">The Offering</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_16" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">8</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_19" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Risk Factors</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_19" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">9</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_22" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Use of Proceeds</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_22" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_25" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Dividend Policy</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_25" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">13</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_28" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Dilution</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_28" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">13</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_31" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Material U.S. Federal Income Tax Cons</a><a href="#if198fbfccf55490aa8d53f15a6567c71_31" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">iderations For</a><a href="#if198fbfccf55490aa8d53f15a6567c71_31" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"> To Non-U.S. Holders</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_31" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">14</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_34" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Underwriting</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_34" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">19</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_37" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Legal Matters</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_37" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">27</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_40" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Experts</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_40" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">27</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_43" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Where You Can Find </a><a href="#if198fbfccf55490aa8d53f15a6567c71_43" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">More</a><a href="#if198fbfccf55490aa8d53f15a6567c71_43" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"> Information</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_43" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">27</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_46" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Incorporation</a><a href="#if198fbfccf55490aa8d53f15a6567c71_46" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"> of Certain Information</a><a href="#if198fbfccf55490aa8d53f15a6567c71_46" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"> by Reference</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">S-<a href="#if198fbfccf55490aa8d53f15a6567c71_46" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">28</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_49" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">Prospectus</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_55" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">ABOUT THIS PROSPECTUS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_55" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">2</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_58" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">RISK FACTORS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_58" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">9</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_19" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_61" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">9</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_64" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_64" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_67" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">DESCRIPTION OF CAPITAL STOCK</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_67" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_70" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">DESCRIPTION OF DEBT SECURITIES</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_70" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_73" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">DESCRIPTION OF WARRANTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_73" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">18</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_76" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">DESCRIPTION OF UNITS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_76" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">20</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_79" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">LEGAL OWNERSHIP OF SECURITIES</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_79" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">21</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_82" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_82" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">24</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_85" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_85" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_88" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">EXPERTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_88" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_91" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">WHERE YOU CAN FIND MORE INFORMATION</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_91" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_94" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: underline;">INCORPORATION OF DOCUMENTS BY REFERENCE</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><a href="#if198fbfccf55490aa8d53f15a6567c71_94" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration: none;">27</a></font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-i</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ABOUT THIS PROSPECTUS SUPPLEMENT</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This prospectus supplement relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus supplement, together with the accompanying prospectus and the information incorporated by reference as described under the heading &#8220;Where You Can Find More Information&#59; Incorporation by Reference.&#8221; This prospectus supplement is deemed a prospectus supplement to the accompanying prospectus contained in the registration statement of which this prospectus supplement forms a part. These documents contain important information that you should consider when making your investment decision.</font></div><div style="text-indent:36pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                This prospectus supplement describes the specific terms of the common stock we are offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the accompanying prospectus and the information contained in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference into this prospectus supplement&#8212;the statement in the document having the later date modifies or supersedes the earlier statement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus or contained in any free writing prospectus prepared by or on our behalf. We have not, and the underwriters have not, authorized anyone to provide you with different information. The distribution of this prospectus supplement and sale of these securities in certain jurisdictions may be restricted by law. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                Trademarks, service marks or trade names of any other companies appearing in this prospectus supplement are the property of their respective owners. Use or display by us of trademarks, service marks or trade names owned by others is not intended to and does not imply a relationship between us and, or endorsement or sponsorship by, the owners of the trademarks, service marks or trade names.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_10"></div><div style="text-align:center;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference therein contain, in addition to historical information, certain forward-looking statements. within the meaning of Section 27A of the Securities Act or 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended, that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and&#47;or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.</font></div><div><font><br></font></div><div style="text-indent:42.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In some cases, you can identify forward-looking statements by terminology, such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;may,&#8221; &#8220;should&#8221;, &#8220;could&#8221; or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus supplement or incorporated herein by reference.</font></div><div><font><br></font></div><div style="text-indent:42.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from those expressed or implied in our written or oral forward-looking statements may be found in this prospectus supplement under the heading &#8220;Risk Factors&#8221; and in our Annual Report on Form 10-K for the year ended December 31, 2019 under the headings &#8220;Risk Factors&#8221; and &#8220;Business,&#8221; as updated in our Quarterly Report(s) on Form 10-Q.</font></div><div><font><br></font></div><div style="text-indent:42.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</font></div><div><font><br></font></div><div style="text-indent:42.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus supplement and incorporated herein by reference, and particularly our forward-looking statements, by these cautionary statements.</font></div><div style="text-indent:42.85pt;text-align:justify;"><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_13"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PROSPECTUS SUPPLEMENT SUMMARY</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">The following summary highlights certain of the information contained elsewhere in or incorporated by reference into this prospectus supplement. Because this is only a summary, however, it does not contain all the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in or incorporated by reference into this prospectus supplement. Before you make an investment decision, you should read this entire prospectus supplement and the accompanying prospectus carefully, including the risks of investing in our securities discussed under the section of this prospectus supplement entitled &#8220;Risk Factors&#8221; and similar headings in the other documents that are incorporated by reference into this prospectus supplement. You should also carefully read the information incorporated by reference into this prospectus supplement, including our financial statements, and the exhibits to the registration statement of which this prospectus supplement is a part.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Unless the context otherwise requires, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Cardiff&#8221; or the &#8220;Company&#8221; in this prospectus supplement mean Cardiff Oncology,&#160;Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Overview</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#160;</font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We are a clinical stage, biotechnology company, developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, extend duration of response and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We licensed onvansertib from Nerviano Medical Sciences (NMS) in March, 2017, pursuant to a license agreement with NMS dated March 13, 2017. This exclusive, world-wide license agreement includes 3 issued patents for onvansertib which cover composition of matter, salt forms of onvansertib and combination of onvansertib with other drugs. </font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Onvansertib is highly potent against the PLK1 enzyme (concentration for 50% inhibition &#91;IC50&#93; &#61; 2nM), whereas low or no activity was observed on a panel of 63 kinases (IC50&#62;500 nM), including the PLK members PLK2 and PLK3 (IC50&#62;10 &#956;M).  Onvansertib was developed to have ideal pharmacokinetics, including oral bioavailability and administration and a drug half-life of approximately 24 hours, allowing for flexible dosing and scheduling, and is well tolerated and safe with only mild to moderate side effects reported to-date. A Phase 1 safety study of onvansertib was successfully completed in patients with advanced metastatic solid tumors and published in 2017 in Investigational New Drugs. </font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">PLK1, a serine&#47;threonine kinase, is a master regulator of mitotic progression with various roles and localizations during the different mitotic phases. Upon PLK1 depletion in cancer cells by RNA interference (RNAi), inhibition of proliferation and decreased viability, resulting from cell cycle arrest with 4N DNA content followed by apoptosis, are observed. PLK1 depletion also results in an increase in the number of cells containing abnormal spindle formation and misaligned chromosomes. Expression of PLK1 is seen in all proliferating normal tissues, and PLK1 is overexpressed in a number of tumors (including breast, prostate, ovary, lung, gastric and colon cancers), as well as in hematologic cancers.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Onvansertib has been tested for antiproliferative activity on a panel of 148 tumor cell lines and appeared highly active with an IC50 (a measure concentration for 50% target inhibition) below 100 nM in 75 cell lines and IC50 values below 1 uM in 133 out of 148 cell lines. Onvansertib also appears active in cells expressing multi-drug resistant (&#8220;MDR&#8221;) transporter proteins and we believe its apparent ability to overcome the MDR transporter resistance mechanism in cancer cells could prove useful in broader drug combination applications.  Additionally, onvansertib has been tested in in-vivo xenograft and transgenic models of different cancer types with the demonstration of tumor growth inhibition or tumor regression.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In in-vitro and in-vivo preclinical studies, synergy (interaction of discrete drugs such that the total effect is greater than the sum of the individual effects) has been demonstrated with onvansertib when used in combination with numerous different chemotherapies, including irinotecan, 5-FU, cisplatin, cytarabine, doxorubicin, gemcitabine and paclitaxel, as well as targeted therapeutics, such as abiraterone acetate (Zytiga</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">), histone deacetylase (&#8220;HDAC&#8221;) inhibitors, such as belinostat (Beleodaq</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">), quizartinib (AC220), a development stage FLT3 inhibitor, and bortezomib (Velcade</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">). These therapies are used clinically for the treatment of solid tumor cancers, leukemias and lymphomas including metastatic colorectal cancer (&#34;mCRC'), metastatic castration resistant prostate cancer (&#34;mCRPC&#34;), pancreatic cancer, triple negative breast cancer (&#8220;TNBC&#8221;), AML and other hematological malignancies. </font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We believe the high-selectivity of onvansertib to PLK1, its 24-hour half-life and oral bioavailability, as well as its demonstrated safety and tolerability, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%;">Clinical Program Updates</font></div><div><font><br></font></div><div style="text-indent:33.75pt;margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We currently have three active clinical trials&#58; </font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">TROV-054 is a Phase 1b&#47;2 open-label clinical trial of onvansertib in combination with FOLFIRI and bevacizumab (Avastin</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;) </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">for the second line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), which is being conducted at USC Norris Comprehensive Cancer Center and The Mayo Clinic Cancer Centers&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">TROV-053 is a Phase 2 open-label clinical trial of onvansertib in combination with abiraterone acetate (Zytiga</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC), which is being conducted at Beth Israel Deaconess Medical Center (&#34;BIDMC&#34;), Dana-Farber Cancer Institute (&#34;DFCI&#34;), and Massachusetts General Hospital (&#34;MGH&#34;)&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">TROV-052 is a Phase 2 open-label clinical trial of onvansertib in combination with standard-of-care chemotherapy, decitabine, in patients with relapsed or refractory acute myeloid leukemia (AML), which is being conducted at nine sites across the U.S. The Phase 1b portion of the AML trial was completed in the fourth quarter of 2019.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:103%;">KRAS-mutated mCRC</font></div><div><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">TROV-054 is a Phase 1b&#47;2 Study of onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer in combination with standard-of-care FOLFIRI and bevacizumab (Avastin</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">).</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The primary objective of this study is to evaluate the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab (Phase 2).</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The rationale for this clinical trial is based on three key principles including synthetic lethality, synergy and proof-of-concept clinical benefit. Synthetic lethality arises when a combination of deficiencies in the expression of two or more genes leads to cell death, whereas a deficiency in only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of one of the genes. In reference to onvansertib, CRC tumor cells harboring KRAS mutations are more vulnerable to cell death with PLK1 inhibition and KRAS-mutated cells are more sensitive to onvansertib than KRAS wild-type isogenic cells. Synergy occurs when the combination of two drugs results in activity greater than that of each individual drug. Onvansertib in combination with irinotecan and 5-FU (components of FOLFIRI) demonstrate synergy in colorectal cancer cell lines and the combination has demonstrated significantly greater tumor growth inhibition than either drug alone.  Proof-of-concept clinical response has been demonstrated in a previously completed Phase 1 trial in solid tumors in which 3 of 5 patients showing stable disease had a KRAS mutation&#59; 2 in colorectal cancer and 1 in pancreatic cancer.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Data presented on September 17, 2020, at the European Society for Medical Oncology (ESMO) conference, demonstrated the safety and efficacy of onvansertib.  Of the 11 patients evaluable for efficacy, </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10 of 11 (91%) patients achieved disease control (SD &#8211; stable disease plus PR &#8211; partial response) with only 1 patient progressing in &#60;6 months while on treatment. Five (45%) patients achieved a partial response (PR)&#59; 4 patients had a confirmed PR (&#8805; 30% tumor shrinkage) with 1 patient going on to curative surgery&#59; 1 patient with an initial PR went off study prior to confirmatory scan due to a non-treatment related event. All 5 PRs were associated with different KRAS mutation variants, including the most common that comprise nearly 80% of mutations in CRC. Eight of 11 (73%) patients demonstrated durable response ranging from 6 to &#62;12 months, and 4 patients remain on treatment. Onvansertib in combination with FOLFIRI and bevacizumab is safe and well tolerated with only 9% of adverse events being grade 3 or 4 and all being resolved within 2.5 weeks. Of the 11 patients, eight had previously received bevacizumab as first line treatment, including the 4 patients who remain on treatment.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:103%;">Key News Releases</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">On September 17, 2020, we announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC) patients at the European Society of Medical Oncology (ESMO) Virtual Congress 2020.</font></div><div><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">On June 9, 2020, we announced the initiation of our Expanded Access Program (EAP) for onvansertib, in combination with standard-of-care FOLFIRI and bevacizumab, for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). This announcement followed the FDA granting Fast Track Designation for onvansertib in KRAS-mutated mCRC.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">On May 13, 2020, we announced an agreement with PoC Capital, LLC, to fund the completion of our ongoing Phase 1b&#47;2 clinical trial in patients with KRAS-mutated metastatic Colorectal Cancer (mCRC). Our agreement with PoC Capital follows the Company's announcement of positive safety and efficacy data from our Phase 1b trial, presented at the American Association for Cancer Research (AACR) conference.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">On April 28, 2020, we announced new positive results from our ongoing Phase 1b&#47;2 clinical trial of onvansertib in combination with FOLFIRI and bevacizumab (Avastin</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The data were featured in a virtual oral presentation, delivered by Dr. Afsaneh Barzi, at the American Association for Cancer Research (AACR) conference on Monday, April 27th, 2020.  At the time of this presentation the Phase 1b&#47;2 trial had enrolled 12 patients, with 88% response in 7 of 8 evaluable patients&#59; 3 patients with a partial response (PR)&#59; 4 patients with stable disease (SD). Data showed median progression-free survival (PFS) of at least 6.5 months with 6 patients continuing on treatment&#59; one patient went on to have successful curative surgery. The biomarker used in this trial is changes in KRAS mutation blood levels&#59; decreases to non-detectable levels in cycle one of treatment is predictive of future tumor regression and response.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:103%;">mCRPC</font></div><div><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">TROV-053 is a Phase 2 Study of onvansertib in combination with Zytiga</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (abiraterone) and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The primary objective of this study is to observe the effects of onvansertib in combination with abiraterone and prednisone on disease control as assessed by prostate specific antigen (PSA) decline or stabilization after 12 weeks of study treatment in patients with mCRPC showing early signs of resistance to abiraterone.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The rationale for this trial is based on the mechanism of action (MOA) of onvansertib and Zytiga and the synergy of these two drugs when used in combination. Onvansertib inhibits tumor cell division (mitosis) by inducing G2&#47;M arrest of tumor cells and the combination of onvansertib and Zytiga significantly increases mitotic arrest and is synergistic when used in combination.  Additionally, PLK1 inhibition appears to enhance the efficacy of androgen signaling blockade in castration-resistant prostate cancer.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Data presented on February 13, 2020, at the American Society for Clinical Oncology Genitourinary Cancers (ASCO GU) conference, demonstrated the safety and efficacy of onvansertib have been demonstrated in patients. Overall, 63% (12 of 19) of evaluable patients achieved partial response (PR) or stable disease (SD) following 12 weeks of treatment with onvansertib and Zytiga. Response to treatment is evaluated based on prostate specific antigen (PSA) values (primary endpoint) and radiographic scans.  Additionally, onvansertib-induced circulating tumor cell (CTC) decrease has been shown to be associated with progression-free survival. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:103%;">AML</font></div><div><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">TROV-052 is a Phase 2 Study of onvansertib in combination with standard-of-care chemotherapy, decitabine, for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).  The Phase 1b portion of this trial was completed in the fourth quarter of 2019.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The objective of this trial is to evaluate the DLTs and MTD or RP2D of onvansertib (Phase 1b &#8211; completed in October 2019). In Phase 2, the objective is to assess the safety, tolerability and preliminary efficacy of the combination of onvansertib at the RP2D and decitabine in patients with relapsed or refractory AML. Additionally, as a correlative objective, this trial is evaluating potential pharmacodynamic (PD) and diagnostic biomarkers of onvansertib in patients with AML. We were granted Orphan Drug Designation (ODD) for onvansertib for the treatment of AML from the FDA and the European Commission.</font></div><div><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The rationale for this trial is based on the need for new and better therapeutic options for patients in the relapsed or refractory AML setting. Current treatment options are often limited by the patient&#8217;s age and health status. Combination treatment with onvansertib and standard-of-care chemotherapy may provide a new safe and effective therapeutic option.</font></div><div><font><br></font></div><div style="text-indent:33.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Data presented on June 12, 2020 at the European Hematology Association (EHA) conference, demonstrated the safety and efficacy of onvansertib in patients. In the completed Phase 1b portion of this trial, the recommended Phase 2 dose (RP2D) was established at onvansertib 60 mg&#47;m</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Onvansertib adverse events were primarily on-target hematological events, in accordance with the mechanism of action, and were reversible and manageable. Anti-leukemic activity was observed at a wide range of onvansertib dose levels (27 to 90 mg&#47;m</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) and the complete response rate achieved in patients was 24% through all dose levels, and 31% at the 4 higher dose levels (27 to 90 mg&#47;m</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">). Decreases in mutant ctDNA after 1 cycle of treatment were highly predictive of clinical response and target engagement (biomarker positivity) in circulating blast cells was associated with a greater decrease in bone marrow blast cells. Phase 2 is enrolling patients and is ongoing.</font></div><div style="text-indent:33.75pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company Information</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We were incorporated in the State of Florida on April&#160;26, 2002. On July&#160;2, 2004, we acquired Xenomics, a California corporation, which was in business to develop and commercialize urine-based molecular diagnostics technology. In 2007, we changed our fiscal year end from January&#160;31 to December&#160;31 and in January&#160;2010, we re-domesticated our state of incorporation from Florida to Delaware and our name was changed to Trovagene,&#160;Inc. On May&#160;6, 2020, we announced a change in our company name from Trovagene,&#160;Inc. to Cardiff Oncology,&#160;Inc.&#160;We have trademarks for the name TROVAGENE, TROVAGENE PRECISION CANCER MEDICINE, TROVAGENE ONCOLOGY and PIPELINE WITHIN A MOLECULE and we have applied for the trademark for Cardiff Oncology. Our principal executive offices are located at 11055 Flintkote Avenue, San Diego, CA 92121, and our telephone number is 858-952-7570. Our website address is</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#160;www.cardiffoncology.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The information on our website is not part of this prospectus. We have included our website address as a factual reference and do not intend it to be an active link to our website.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_16"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">THE OFFERING</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:36.583%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.565%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:57.552%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock offered by us</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,500,000 shares (or 7,475,000 shares if the underwriters exercise their option to purchase additional shares in full).</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock to be outstanding immediately after this offering</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,175,945 shares (or 31,150,945 shares if the underwriters exercise their option to purchase additional shares in full).</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option to purchase additional shares</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We have granted the underwriters an option to purchase up to 975,000 additional shares of our common stock. This option is exercisable, in whole or in part, for a period of up to 30 days from the date of this prospectus supplement.</font></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Use of proceeds</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We intend to use the net proceeds from this offering for clinical development of our product candidate, working capital and other general corporate purposes. We may also use a portion of the remaining net proceeds, if any, to acquire or invest in complementary businesses, products and technologies, although we have no current commitments or agreements with respect to any acquisitions as of the date hereof. See &#8220;Use of Proceeds&#8221; on page S-10. </font></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk factors</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">See &#8220;Risk Factors&#8221; beginning on page S-9 of this prospectus supplement, page 28 of the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement for a discussion of factors you should carefully consider before deciding to invest in our common stock.</font></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nasdaq Capital Market symbol</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8220;CRDF&#8221;</font></td></tr></table></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Unless we indicate otherwise, all information in this prospectus supplement&#160;is based on 23,675,945 shares of common stock outstanding as of August 31, 2020 and&#160;excludes as of that date&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 877 shares of common stock issuable upon conversion of outstanding Series&#160;A Convertible Preferred Stock&#59;</font></div><div style="text-indent:18pt;"><font><br></font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 3,548,459 shares of common stock issuable upon conversion of outstanding Series&#160;E Convertible Preferred Stock&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 1,924,039 shares of our common stock issuable upon exercise of outstanding stock options under our stock incentive plans at a weighted average exercise price of $7.64 per share&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 9,979,566 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $4.27 per share&#59; and</font></div><div><font><br></font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 258,497 shares of common stock reserved for future grants and awards under our stock incentive plans.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-8</font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RISK FACTORS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider carefully the risks described below and discussed under the section captioned &#8220;Risk Factors&#8221; in our most recent Annual Report on Form&#160;10-K and any subsequent Quarterly Reports on Form&#160;10-Q, which are each incorporated by reference in this prospectus supplement and the accompanying prospectus in their entirety, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC, together with other information in this prospectus supplement, the accompanying prospectus, and the information and documents incorporated by reference that we have authorized for use in connection with this offering. If any of these risks actually occur, our business, financial condition, results of operations or cash flows could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Risks Related to this Offering</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">You will experience immediate dilution in the net tangible book value per share of the common stock you purchase.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:20.25pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Since the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our common stock, you will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering. Based on a public offering price of $13.50 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, and based on a net tangible book value of our common stock of $1.14 per share as of June 30, 2020, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $9.85 per share in the net tangible book value of common stock. See &#8220;Dilution&#8221; for a more detailed discussion of the dilution you will incur if you purchase shares of common stock in this offering</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Because we will have broad discretion and flexibility in how the net proceeds from this offering are used, we may use the net proceeds in ways in which you disagree.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:20.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We intend to use the net proceeds from this offering for clinical development of our product candidate, working capital and other general corporate purposes.&#160; See &#8220;Use of Proceeds&#8221; on page&#160;S-12. We have not allocated specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">You may experience future dilution as a result of future equity offerings and other issuances of our securities. In addition, this offering and future equity offerings and other issuances of our common stock or other securities may adversely affect our common stock price.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the same as the price per share in this offering. We may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or securities convertible into common stock in future transactions may be higher or lower than the price per share in this offering. You will incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of common stock under our stock incentive programs. In addition, the sale of shares in this offering and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock.</font></div><div style="text-indent:36pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">The outbreak of the novel coronavirus disease, COVID-19, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.</font></div><div><font><br></font></div><div style="text-indent:30.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In January 2020, the World Health Organization declared the outbreak of COVID-19 as a &#8220;Public Health Emergency of International Concern,&#8221; which continues to spread throughout the world and has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. We continue to monitor the impact of the COVID-19 outbreak closely. The extent to which the COVID-19 outbreak will impact our operations or financial results is uncertain.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">            The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred&#59; supply chains have been disrupted&#59; facilities and production have been suspended&#59; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material adverse effect on our business, financial condition and results of operations. As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business and clinical trials, including&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:3.432%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.262%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.262%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:87.644%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">delays or difficulties in enrolling and retaining patients in our clinical trials&#59;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints&#59;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:3.432%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.262%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.262%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:87.644%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines&#59;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">interruption of, or delays in receiving, supplies of our product candidate from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems&#59;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">limitations on employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">interruption or delays to our sourced clinical activities&#59; and</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">changes in clinical site procedures and requirements as well as regulatory requirements for conducting clinical trials during the pandemic.</font></td></tr></table></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued guidance, which FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the trial, and any disruption of the trial as a result of the COVID-19 pandemic&#59; a list of all subjects affected by the COVID-19 pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered&#59; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and&#47;or study, alternative procedures used to collect critical safety and&#47;or efficacy data) on the safety and efficacy results reported for the trial.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:30.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The COVID-19 pandemic continues to revolve rapidly, with the status of operations and government restrictions evolving weekly. The extent to which the outbreak impacts our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</font></div><div style="text-indent:30.6pt;"><font><br></font></div><div style="text-indent:30.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions taken to contain COVID-19 or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely.</font></div><div style="text-indent:30.6pt;"><font><br></font></div><div style="text-indent:30.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In addition, our business could be materially adversely affected by other business disruptions to us or our third-party providers that could materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our CROs, contract manufacturing organizations, or CMOs, and other contractors, consultants and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications failures, water </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could materially adversely affect our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidate. Our ability to obtain clinical supplies of our product candidate could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</font></div><div style="text-indent:36pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock for any return on their investment.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We have never declared or paid cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.</font></div><div style="text-indent:36pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;">We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We are currently a &#8220;smaller reporting company&#8221;, as defined in Rule 405 under the Securities Act.  As a smaller reporting company, we take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;smaller reporting companies,&#8221; including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the provisions of Section 404(b) of the Sarbanes-Oxley Act of 2002 requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting. Decreased disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_22"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">USE OF PROCEEDS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We expect to receive net proceeds of approximately $81.7 million in this offering, or approximately $94.0 million if the underwriters exercise their option to purchase additional shares in full, in each case, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We intend to use the net proceeds from the sale of the shares for clinical development of our product candidate, working capital and for other general corporate purposes. The amounts and timing of our use of proceeds will vary depending on a number of factors, including the amount of cash generated or used by our operations. As a result, we will retain broad discretion in the allocation of the net proceeds of this offering.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We may also use a portion of the remaining net proceeds, if any, to acquire or invest in complementary businesses, products and technologies, although we have no current commitments or agreements with respect to any acquisitions as of the date hereof</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div id="if198fbfccf55490aa8d53f15a6567c71_25"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DIVIDEND POLICY</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We have never declared or paid cash dividends on our common stock. We currently intend to retain our future earnings, if any, for use in our business and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs and plans for expansion.&#160; Pursuant to the terms of the Series&#160;A Convertible Preferred Stock, dividends cannot be paid to the holders of our common stock so long as any dividends due on the Series&#160;A Convertible Preferred Stock remain unpaid.</font></div><div style="text-indent:36pt;"><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_28"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DILUTION</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per share and the as adjusted net tangible book value per share after this offering. As of June 30, 2020, our net tangible book value was $24.4 million, or $1.14 per share. Net tangible book value per share represents our total tangible assets (excluding deferred issuance costs) less our total liabilities, divided by the number of shares outstanding. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Our pro forma net tangible book value as of June 30, 2020 is approximately $28.4 million, or approximately $1.20 per share of our common stock, after giving effect to the exercise of warrants to purchase 2,349,869 shares of common stock during July and August 2020.   </font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">After giving effect to the sale of 6,500,000 shares in this offering at the public offering price of $13.50 per share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value per share as of June 30, 2020 would have been approximately $110.1 million, or $3.65 per share. This represents an immediate increase in net tangible book value per share of our common stock of approximately $2.45  per share to existing stockholders and an immediate dilution of approximately $9.85  per share to purchasers in this offering.  The following table illustrates this per share dilution&#58;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%;"><tr><td style="width:1.0%;"></td><td style="width:71.640%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.788%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.792%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Public offering price per share</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.50</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pro forma net tangible book value per share as of June 30, 2020</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.20</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in pro forma net tangible per share attributable to this offering</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.45</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Pro forma as adjusted net tangible book value per share as of June 30, 2020</font></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.65</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilution in net tangible book value per share to new investors in this offering</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.85</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If the underwriters exercise in full their option to purchase up to 975,000 additional shares of common stock at the public offering price of $13.50 per share, the pro forma as adjusted net tangible book value would be $3.93 per share, the increase in net tangible book value per share to existing stockholders would be $0.28 per share and the immediate dilution to new investors purchasing shares in this offering would be $9.57 per share.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The above discussion and table is based on 21,325,076 shares of common stock outstanding as of June 30, 2020 and excludes as of that date&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 877 shares of common stock issuable upon conversion of outstanding Series&#160;A Convertible Preferred Stock&#59;</font></div><div style="text-indent:18pt;"><font><br></font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 3,548,459 shares of common stock issuable upon conversion of outstanding Series&#160;E Convertible Preferred Stock&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 1,924,039 shares of our common stock issuable upon exercise of outstanding stock options under our stock incentive plans at a weighted average exercise price of $7.64 per share&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 12,329,435 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $3.78 per share&#59; and</font></div><div><font><br></font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#183; 258,497 shares of common stock reserved for future grants and awards under our stock incentive plans.</font></div><div><font><br></font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_31"></div><div style="text-indent:36pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR NON-U.S. HOLDERS</font></div><div style="text-indent:36pt;text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#8220;IRS&#8221;), in each case in effect as of the date hereof all of which are subject to change possibly with retroactive effect. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                This discussion is limited to Non-U.S. Holders that hold our common stock as a &#8220;capital asset&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder&#8217;s particular circumstances, including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation&#58;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:3.139%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.723%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.992%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:89.546%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. expatriates and former citizens or long-term residents of the United States&#59;</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment&#59;</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">banks, insurance companies, and other financial institutions&#59;</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">brokers, dealers or traders in securities&#59;</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax&#59;</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">tax-exempt organizations or governmental organizations&#59;</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">persons deemed to sell our common stock under the constructive sale provisions of the Code&#59;</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation&#59;</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">tax-qualified retirement plans&#59;</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8220;qualified foreign pension funds&#8221; as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds&#59; and</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">persons subject to special tax accounting rules as a result of any item of gross income with respect to the stock being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code).</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">               </font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">THIS DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX OR LEGAL ADVICE. INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Definition of a Non-U.S. Holder</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For purposes of this discussion, a &#8220;Non-U.S. Holder&#8221; is any beneficial owner of our common stock that is neither a &#8220;U.S. person&#8221; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following&#58;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:3.139%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.723%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.992%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:89.546%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">an individual who is a citizen or resident of the United States&#59;</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a corporation created or organized under the laws of the United States, any state thereof&#59;</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">an estate, the income of which is subject to U.S. federal income tax regardless of its source&#59; or</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a trust that (1) is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Distributions</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">As described in the section entitled &#8220;Dividend Policy,&#8221; we do not anticipate paying any cash dividends in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S. Holder&#8217;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#8220;-Sale or Other Taxable Disposition.&#8221;</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the lower treaty rate). If a Non-U.S. Holder holds the stock through a financial institution or other intermediary, the Non-U.S. Holder will be required to provide appropriate documentation to the intermediary, which then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their own tax advisors regarding their entitlement to benefits under any applicable income tax treaty.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their own tax advisors regarding any applicable tax treaties that may provide for different rules.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Sale or Other Taxable Disposition</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                A Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:3.139%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.723%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.992%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:89.546%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable)&#59;</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the Non-U.S.  Holder is a nonresident alien individual who is present in the United States for 183  days or more during the taxable year of the disposition and certain other requirements and conditions are met, in which case the Non-U.S. Holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the Non-U.S. Holder, if any (even though the individual is not considered a resident of the United States), provided that the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses&#59; or</font></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">our common stock constitutes a U.S. real property interest by reason of our status as a &#8220;U.S. real property holding corporation,&#8221; or a USRPHC, for U.S. federal income tax purposes, at any time within the shorter of the five-year period preceding the disposition or the non-U.S. holder&#8217;s holding period for our common stock. We believe we are not currently and do not anticipate becoming a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other business assets, there can be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, gain arising from the sale or other taxable disposition by a Non-U.S.Holder of a class of our capital stock will not be subject to U.S. federal income tax as long as such class of stock is &#8220;regularly traded&#8221;, as defined by applicable Treasury Regulations, on an established securities market and such Non-U.S. Holder does not, actually or constructively, hold more than five percent of such class of stock at any time during the applicable period that is specified in the Code. If the foregoing exception does not apply, then if we are or were to become a USRPHC a purchaser may be required to withhold 15% of the proceeds payable to a non-U.S. holder from a sale of our common stock and such Non-U.S. Holder generally will be subject to U.S. federal income tax on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code).</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Information Reporting and Backup Withholding</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the Non-U.S. Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.</font></div><div style="text-indent:36pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Additional Withholding Tax on Payments Made to Foreign Accounts</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or &#8220;FATCA&#8221;) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock paid to a &#8220;foreign financial institution&#8221; or a &#8220;non-financial foreign entity&#8221; (each as defined in the Code), unless (1) the foreign financial institution undertakes certain diligence and reporting obligations, (2) the non-financial foreign entity either certifies it does not have any &#8220;substantial United States owners&#8221; (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1) above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#8220;specified United States persons&#8221; or &#8220;United States-owned foreign entities&#8221; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of such stock on or after January 1, 2019, recently proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.</font></div><div style="text-indent:36pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                Prospective investors should consult their own tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-18</font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">UNDERWRITING</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the common stock being offered.  Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of shares of our common stock set forth opposite its name below.  Cowen and Company, LLC and Piper Sandler &#38; Co. are the representatives of the underwriters.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.046%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.399%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.542%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.413%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Underwriter</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Cowen and Company, LLC</font></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,697,500</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Piper Sandler &#38; Co.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,502,500</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">H.C. Wainwright &#38; Co., LLC</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,300,000</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,500,000</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent and that the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the option to purchase additional shares described below.  If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased, or the underwriting agreement may be terminated.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act of 1933, and to contribute to payments the underwriters may be required to make in respect thereof. </font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement.  The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Option to Purchase Additional Shares. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> We have granted to the underwriters an option to purchase up to 975,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.  This option is exercisable for a period of 30 days.  To the extent that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Discounts and Commissions. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> The following table shows the public offering price, underwriting discounts and commissions and proceeds, before expenses to us.  These amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares. </font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We estimate that the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $200,000 and are payable by us.  We have agreed to reimburse the underwriters up to $125,000 for fees, disbursements and expenses of underwriters&#8217; counsel. In addition, we have agreed to reimburse the underwriters for their legal counsel fees related to FINRA matters. In accordance with FINRA Rule 5110, these reimbursed fees are deemed underwriting compensation for this offering.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:42.172%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.870%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.870%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.896%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.176%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.411%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.093%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.025%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.870%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.093%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.724%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Per Share</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Without Option</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">With Option</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Public offering price</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.50</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,750,000</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,912,500</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Underwriting discounts and commissions</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8775</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,703,750</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,559,313</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds, before expenses, to Company</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.6225</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82,046,250</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,353,188</font><font style="font-size:12pt;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">              </font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The underwriters propose to offer the shares of common stock to the public at the public offering price set forth on the cover of this prospectus supplement.  The underwriters may offer the shares of common stock to securities dealers at the public offering price less a concession not in excess of $0.5265 per share. If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Discretionary Accounts.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The underwriters do not intend to confirm sales of the shares to any accounts over which they have discretionary authority.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;CRDF&#8221;.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Stabilization. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> In connection with this offering, the underwriters may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Overallotment transactions involve sales by the underwriters of shares of common stock in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position.  In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the option to purchase additional shares.  In a naked short position, the number of shares involved is greater than the number of shares in the option to purchase additional shares.  The underwriters may close out any short position by exercising their option to purchase additional shares and&#47;or purchasing shares in the open market. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been completed in order to cover syndicate short positions.  In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the option to purchase additional shares. If the underwriters sell more shares than could be covered by exercise of the option to purchase additional shares and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock.  As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions.  Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on the Nasdaq Stock Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Passive Market Making. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M under the Securities Exchange Act of 1934, as amended, during a period before the commencement of offers or sales of common stock and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security.  However, if all independent bids are lowered below the passive market maker&#8217;s bid, such bid must then be lowered when specified purchase limits are exceeded.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Lock-Up Agreements. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Pursuant to certain &#8216;&#8216;lock-up&#8217;&#8217; agreements, we and our executive officers and directors , have agreed, subject to certain exceptions, not to and will not cause or direct any of our affiliates to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into, or announce the intention to enter into any swap, hedge or similar agreement or arrangement (including, without limitation, the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) that transfers, is designed to transfer or reasonably could be expected to transfer (whether by the stockholder or someone other than the stockholder) that transfers, in whole or in part, directly or indirectly the economic consequence of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file with the SEC a registration statement under the Securities Act relating to, any common stock or securities convertible into or exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC and Piper Sandler &#38; Co., for a period of 90 days after the date of the pricing of the offering.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for common stock.  It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. The exceptions permit us, among other things and subject to restrictions, to&#58; (a) issue common stock or options pursuant to employee benefit plans, (b) issue common stock upon exercise of outstanding options or warrants (c) issue securities in connection with acquisitions or similar transactions, or (d) file registration statements on Form S-8. The exceptions permit parties to the &#8216;&#8216;lock-up&#8217;&#8217; agreements, among other things and subject to restrictions, to&#58;  (a) make certain gifts, (b) if the party is a corporation, partnership, limited liability company or other business entity, make transfers to any shareholders, partners, members of, or owners of similar equity interests in, the party, or to an affiliate of the party, if such transfer is not for </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">value, and (c) if the party is a corporation, partnership, limited liability company or other business entity, make transfers in connection with the sale or transfer of all of the party&#8217;s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the party&#8217;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by the &#8220;lock-up&#8221; agreement and (d) participate in tenders involving the acquisition of a majority of our stock.  In addition, the lock-up provision will not restrict broker-dealers from engaging in market making and similar activities conducted in the ordinary course of their business.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Cowen and Company, LLC and Piper Sandler &#38; Co., in their sole discretion, may release our common stock and other securities subject to the lock-up agreements described above in whole or in part at any time.  When determining whether or not to release our common stock and other securities from lock-up agreements, Cowen and Company, LLC and Piper Sandler &#38; Co. will consider, among other factors, the holder&#8217;s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time of the request.   </font></div><div style="text-indent:36pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Selling Restrictions</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Canada</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Prospectus Exemptions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or subsection 73.3(1) of the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Securities Act </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(Ontario), and are permitted clients, as defined in National Instrument 31-103 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Registration Requirements, Exemptions and Ongoing Registrant Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any resale of the common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory.  The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Pursuant to section 3A.3 of National Instrument 33-105 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Underwriting Conflicts </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Switzerland. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> The securities will not be offered, directly or indirectly, to the public in Switzerland and this prospectus supplement does not constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">European Economic Area and the United Kingdom. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In relation to each Member State of the European Economic Area and the United Kingdom (each, a &#8220;Member State&#8221;), no shares have been offered or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">except that offers of shares may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation&#58;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A.            to any legal entity which is a qualified investor as defined under the Prospectus Regulation&#59;</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">B.            to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters&#59; or</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">C.            in any other circumstances falling within Article 1(4) of the Prospectus Regulation,</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Company that it is a &#8220;qualified investor&#8221; within the meaning of Article 2(e) of the Prospectus Regulation.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In the case of any shares being offered to a financial intermediary as that term is used in Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Member State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017&#47;1129.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">References to the Prospectus Regulation includes, in relation to the United Kingdom, the Prospectus Regulation as it forms part of the United Kingdom domestic law by virtue of the European Union (Withdrawal) Act of 2018.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">United Kingdom.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#8220;qualified investors&#8221; (as defined in the Prospectus Regulation) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#8220;Order&#8221;) and&#47;or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order and&#47;or (iii) to whom it may otherwise be lawfully communicated (all such persons together being referred to as &#8220;relevant persons&#8221;) in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Hong Kong.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#8220;SFO&#8221;) of Hong Kong and any rules made thereunder&#59; or (b) in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the &#8220;CO&#8221;), or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made thereunder.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Singapore.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each underwriter has acknowledged that this prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore.  Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus supplement or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than&#58;</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A.  to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section 274 of the SFA&#59;</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">B.  to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA&#59; or</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">C.  otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is&#58;</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A. a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor&#59; or</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b. a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (however described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section 275 of the SFA except&#58;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA&#59;</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii) where no consideration is or will be given for the transfer&#59;</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii) where the transfer is by operation of law&#59;</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv) as specified in Section 276(7) of the SFA&#59; or</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) </font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(Securities and Securities-based Derivatives Contracts) Regulations 2018.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Singapore SFA Product Classification &#8212; In connection with Section 309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section 309A(1) of the SFA), that the shares are &#8220;prescribed capital markets products&#8221; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12&#58; Notice on the Sale of Investment Products and MAS Notice FAA-N16&#58; Notice on Recommendations on Investment Products).</font></div><div><font><br></font></div><div style="text-indent:15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Israel.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In the State of Israel this prospectus supplement shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728 &#8211; 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section 15 of the Israeli Securities Law, 5728&#8211;1968, including, inter alia, if&#58; (i) the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#8220;Addressed Investors&#8221;)&#59; or (ii) the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 &#8211; 1968, subject to certain conditions (the &#8220;Qualified Investors&#8221;).  The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors.  The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 &#8211; 1968.  We have not and will not distribute this prospectus supplement or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors.</font></div><div><font><br></font></div><div style="text-indent:15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968.  In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and&#47;or to anyone acting on our behalf&#58; (i) that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968&#59; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968 regarding Qualified Investors is applicable to it&#59; (iii) that it will abide by all provisions set forth in the Israeli Securities Law, 5728 &#8211; 1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock&#59; (iv) that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 &#8211; 1968&#58; (a) for its own account&#59; (b) for investment purposes only&#59; and (c) not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 &#8211; 1968&#59; and (v) that it is willing to provide further evidence of its Qualified Investor status.  Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">containing, inter alia, the Addressed Investor&#8217;s name, address and passport number or Israeli identification number.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than offers made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further offer of shares on our behalf or on behalf of the underwriters. </font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Electronic Offer, Sale and Distribution of Shares. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically.  The representatives may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders.  Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations.  Other than the prospectus in electronic format, the information on these websites is not part of this prospectus supplement or the registration statement of which this prospectus supplement forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Other Relationships. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Certain of the underwriters and their affiliates have provided, and may in the future provide, various investment banking, commercial banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fees.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-26</font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_37"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LEGAL MATTERS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The validity of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter &#38; Hampton, New York, New York. Certain legal matters in connection with this offering will be passed upon for the underwriters by Dechert LLP.</font></div><div style="text-indent:36pt;"><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_40"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXPERTS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The consolidated financial statements as of December 31, 2019 and 2018 and for the years then ended incorporated by reference in this prospectus supplement have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm (the report on the consolidated financial statements contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern), incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div id="if198fbfccf55490aa8d53f15a6567c71_43"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHERE YOU CAN FIND MORE INFORMATION</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This prospectus supplement constitutes a part of the registration statement on&#160;Form&#160;S-3&#160;that&#160;we have filed with the SEC under the Securities Act. As permitted by the SEC&#8217;s rules, this prospectus supplement and any accompanying prospectus, which forms a part of the registration statement, do not contain all of the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statement made in this prospectus supplement or any accompanying prospectus concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC&#8217;s website at</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#160;http&#58;&#47;&#47;www.sec.gov</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. We also maintain a website at</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#160;www.cardiffoncology.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section&#160;of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC&#160;at&#160;1-800-SEC-0330&#160;for&#160;further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning us at&#58; 11055 Flintkote Avenue, San Diego, California, 92121,&#160;(858)&#160;952-7570.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-27</font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_46"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:49.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This prospectus supplement is part of the registration statement, but the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to &#8220;incorporate by reference&#8221; the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus supplement. Information that is incorporated by reference is considered to be part of this prospectus supplement and you should read it with the same care that you read this prospectus supplement and the accompanying prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus supplement, and will be considered to be a part of this prospectus supplement from the date those documents are filed.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:49.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We incorporate by reference the documents listed below, all filings filed by us pursuant to the Exchange Act after the date of the registration statement of which this prospectus supplement and the accompanying prospectus forms a part, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d)&#160;of the Exchange Act prior to the time that all securities covered by this prospectus supplement have been sold&#59; provided, however, that we are not incorporating any information furnished under either Item 2.02 or Item 7.01 of any current report on&#160;Form&#160;8-K&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020002424/trov-123119x10k.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">our Annual Report on Form 10-K for the year ended December 31, 2019 filed on February 27, 2020</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020006938/trov-033120x10q.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">May 7, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#59;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828020012428/crdf-20200630.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">August 11, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#59;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Our Current Reports on Form 8-K or 8-K&#47;A filed </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020000311/trov8-k011320.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">January 13, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020000403/trov8-k012120.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">January 21, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020000533/trov8-k012720.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">January 27, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020000651/trov8-k012920.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">January 29, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020000797/trov8-k013020.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">January 30, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020001027/trov8-k020520.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">February 5, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020001467/trov8-k021320.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">February 13, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020002429/trov8-k022720earningsrelea.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">February 27, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020003017/trov8-k030520.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">March 5, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="https://www.sec.gov/Archives/edgar/data/1213037/000110465920041147/tm2014279-1_8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">March 31, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020004445/trov8-k040120.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">April 1, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020004781/trov8-k040820.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">April 8, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465920045549/tm2015581-1_8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">April 10, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020005079/trov8-k040620.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">April 17, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020005112/trov8-k041720.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">(2)</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020005226/trov8-k042220.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">April 22, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020005682/trov8-k042820.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">April 28, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020006555/trov8-k050620.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">May 6, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020007644/crdf8-k051320.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">May 13, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020008004/crdf8-k051920.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">May 19, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020008455/crdf8-k052720.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">May 27, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020008504/crdf8-k052820.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">May 28, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020008589/crdf8-k052920.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">May 29, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020009155/crdf8-k060920.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">June 9, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020009417/crdf8-k061520.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">June 15, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020009534/crdf8-k061620.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">June 16, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020009569/crdf8-ka061620.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">June 17, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020009689/crdf8-k061920.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">June 19, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020010960/0001628280-20-010960-index.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">July 30, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020011606/crdf8-k080420.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">August 4, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020013539/crdf8-k091420.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">September 14, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020013580/crdf8-k091520.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">September 15, 2020</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020013690/crdf8-k091720.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;">September 17, 2020</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#59; and</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912039425/a12-9768_98a12b.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">the description of our common stock contained in our Registration Statement on Form 8-A filed with the Commission on May 23, 2012</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:49.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any statements made in a document incorporated by reference in this prospectus supplement are deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement in this prospectus supplement or in any other subsequently filed document, which is also incorporated by reference, modifies or supersedes the statement. Any statement made in this prospectus supplement is deemed to be modified or superseded to the extent a statement in any subsequently filed document, which is incorporated by reference in this prospectus supplement, modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:49.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The information relating to us contained in this prospectus supplement should be read together with the information in the documents incorporated by reference. In addition, certain information, including financial information, contained in this prospectus supplement, the accompanying prospectus or incorporated by reference in this prospectus supplement and the accompanying prospectus should be read in conjunction with documents we have filed with the SEC.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:49.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">We will provide to each person, including any beneficial holder, to whom a prospectus supplement is delivered, at no cost, upon written or oral request, a copy of any or all of the information that has been incorporated by reference in the prospectus supplement but not delivered with the prospectus supplement. Requests for documents should be by writing to or telephoning us at the following address&#58; Cardiff Oncology,&#160;Inc., 11055 Flintkote Avenue, San Diego, CA 92121&#59; (858)&#160;952-7570. Exhibits to these filings will not be sent unless those exhibits have been specifically incorporated by reference in such filings.</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_49"></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">S-29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PROSPECTUS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><img alt="g210381dei0011.jpg" src="g210381dei0011.jpg" style="height:45px;width:150px;"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Trovagene,&#160;Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Debt Securities</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Units</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">We may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $150,000,000.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">This prospectus provides a general description of the securities we may offer.&#160; Each time we sell a particular class or series of securities, we will provide specific terms of the securities offered in a supplement to this prospectus. &#160;The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. You should read carefully this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference herein or therein before you invest in any of our securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in one or more supplements to this prospectus. This prospectus may not be used to consummate sales of any of these securities unless it is accompanied by a prospectus supplement. Before investing, you should carefully read this prospectus and any related prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Our common stock is presently listed on The Nasdaq Capital Market under the symbol &#8220;TROV.&#8221;&#160; On June&#160;21, 2019, the last reported sale price of our common stock was $2.55 per share.&#160; The applicable prospectus supplement will contain information, where applicable, as to any other listing on The Nasdaq Capital Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.&#160; Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">These securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters, dealers, or through a combination of these methods on a continuous or delayed basis. &#160;See &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Plan of Distribution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#8221; in this prospectus. We may also describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from any such sale will also be included in a prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The aggregate market value of our outstanding common stock held by non-affiliates was approximately $19,624,009 which was calculated based on 5,441,363 shares of outstanding common stock held by non-affiliates as of June&#160;24, 2019, and a price per share of $3.62, the closing price of our common stock on May&#160;3, 2019. Pursuant to General Instruction I.B.6 of Form&#160;S-3, in no event will we sell securities pursuant to this registration statement with a value more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75.0 million. In the event that subsequent to the effective date of this registration statement, the aggregate market value of our outstanding common stock held by non-affiliates equals or exceeds $75.0 million, then the one-third limitation on sales shall not apply to additional sales made pursuant to this registration statement. We have sold $3,530,946 of securities pursuant to General Instruction I.B.6 of Form&#160;S-3 during the 12 calendar months prior to, and including, the date of this registration statement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Investing in our securities involves various risks. &#160;See &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;">Risk Factors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">&#8221; contained herein for more information on these risks. Additional risks will be described in the related prospectus supplements under the heading &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;">Risk Factors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">.&#8221; You should review that section of the related prospectus supplements for a discussion of matters that investors in our securities should consider.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus or any accompanying prospectus supplement. &#160;Any representation to the contrary is a criminal offense.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The date of this prospectus is July 1, 2019.</font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_52"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:85.850%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.565%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.285%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_55" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">ABOUT THIS PROSPECTUS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_55" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">2</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_58" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">RISK FACTORS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_58" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">9</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_19" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_61" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">9</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_64" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_64" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_67" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">DESCRIPTION OF CAPITAL STOCK</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_67" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_70" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">DESCRIPTION OF DEBT SECURITIES</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_70" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_73" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">DESCRIPTION OF WARRANTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_73" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">18</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_76" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">DESCRIPTION OF UNITS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_76" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">20</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_79" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">LEGAL OWNERSHIP OF SECURITIES</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_79" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">21</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_82" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_82" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">24</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_85" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_85" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_88" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">EXPERTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_88" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_91" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">WHERE YOU CAN FIND MORE INFORMATION</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_91" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">26</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_94" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">INCORPORATION OF DOCUMENTS BY REFERENCE</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="#if198fbfccf55490aa8d53f15a6567c71_94" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">27</a></font></div></td></tr></table></div><div id="if198fbfccf55490aa8d53f15a6567c71_55"></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ABOUT THIS PROSPECTUS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or SEC, using a &#8220;shelf&#8221; registration process. Under this shelf registration statement, we may sell from time to time in one or more offerings of common stock and preferred stock, various series of debt securities and&#47;or warrants to purchase any of such securities, either individually or as units comprised of a combination of one or more of the other securities in one or more offerings up to a total dollar amount of $150,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell any type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits.&#160; We may add, update or change in a prospectus supplement or free writing prospectus any of the information contained in this prospectus or in the documents we have incorporated by reference into this prospectus. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material information relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement and any related free writing prospectus, together with the additional information described under &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Where You Can Find More Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#8221; before buying any of the securities being offered.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement, or any related free writing prospectus that we may authorize to be provided to you. This prospectus, the accompanying prospectus supplement and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, the accompanying prospectus supplement or any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference (as our business, financial condition, results of operations and prospects may have changed since that date), even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered or securities are sold on a later date.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with the most recent date will control.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As permitted by the rules&#160;and regulations of the SEC, the registration statement, of which this prospectus forms&#160;a part, includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC&#8217;s web site or at the SEC&#8217;s offices described below under the heading &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Where You Can Find Additional Information.&#8221;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Company References</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In this prospectus &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Trovagene,&#160;Inc., a Delaware corporation, and its subsidiaries, unless the context otherwise requires.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SUMMARY</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:2.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical-stage, oncology therapeutics company, taking a precision medicine approach to develop targeted therapies for the treatment of patients with leukemias, lymphomas and solid tumor cancers. By integrating biomarkers into our clinical development programs, we will be able to identify patients who are most likely to respond to treatment across a number of cancer types and associated indications where there is a significant medical need to provide new therapeutic options.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our drug candidate, onvansertib (formerly known as&#160;PCM-075),&#160;is a&#160;first-in-class,&#160;3rd&#160;generation, oral and highly-selective Polo-like Kinase 1 (&#8220;PLK1&#8221;) adenosine triphosphate (&#8220;ATP&#8221;) competitive inhibitor. PLK1 is essential for precisely regulating the cell division and maintaining genome stability in mitosis (cell division), spindle assembly, and DNA damage response. Studies have shown that PLK1 is highly expressed in most cancers, and its over-expression is associated with poor prognosis in patients. Data has shown that blocking the expression of PLK1 by kinase inhibitors can effectively inhibit the proliferation of and induce apoptosis (death) of tumor cells.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March&#160;15, 2017, we announced the licensing of onvansertib&#160;(PCM-075),&#160;a PLK1 inhibitor, from Nerviano Medical Sciences S.r.l. (&#8220;Nerviano&#8221;), the largest oncology research and development company in Italy and a leader in protein kinase drug development (Polo-like Kinase Inhibitors).</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Onvansertib is the only PLK1 selective ATP competitive inhibitor, administered orally with apparent antitumor activity in different preclinical models currently in clinical development. The Polo-like Kinase family consists of 5 members (PLK1-PLK5) and they are involved in multiple functions of cell division, including the regulation of centrosome maturation, checkpoint recovery, spindle assembly, cytokinesis, apoptosis and many others. PLK1 plays a crucial role in the regulation of mitotic checkpoints. The overexpression of PLK1 can lead to immature cell division with aneuploidy, a hallmark of cancer. PLK1 is over-expressed in a wide variety of hematologic and solid tumor malignancies including acute myeloid leukemia, prostate, lung, breast, and colorectal cancer. In addition, several studies have shown that over-expression of PLK1 correlates with poor prognosis.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Onvansertib has been tested in-vivo in different xenograft and transgenic models at times suggesting tumor growth inhibition or tumor regression when used in combination with other therapies. The antiproliferative activity of onvansertib was evaluated on a panel of 148 tumor cell lines and appeared highly active with an IC50&#160;(a measure concentration for 50% target inhibition) below 100 nM in 75 cell lines and IC50&#160;values below 1 uM in 133 out of 148 cell lines.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Onvansertib was developed to have high selectivity for PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to previous pan Polo-like inhibitors. A Phase 1 safety study was successfully completed in patients with advanced metastatic solid tumors and published in 2017 in&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investigational New Drugs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. We have three active Investigational New Drug (&#8220;IND&#8221;) applications in place with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), and three ongoing clinical studies. The first study is&#160;TROV-052 (ClinicalTrials.gov Identifier NCT03303339), a Phase 1b&#47;2 open-label clinical trial of onvansertib in combination with&#160;standard-of-care&#160;low-dosecytarabine (&#8220;LDAC&#8221;) or decitabine for patients with relapsed or refractory Acute Myeloid Leukemia (&#8220;AML&#8221;). The second study is&#160;TROV-053 (ClinicalTrials.gov Identifier NCT03414034), a Phase 2 open-label clinical trial of onvansertib in combination with Zytiga&#174;&#160;(abiraterone acetate)&#47;prednisone, all administered orally, for patients with metastatic Castration-Resistant Prostate Cancer (&#8220;mCRPC&#8221;) and the third study is&#160;TROV-054 (ClincalTrials.gov Identifier NCT03829410), a Phase 1b&#47;2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil and irinotecan) and Avastin&#174;&#160;(bevacizumab) for patients with metastatic Colorectal Cancer (&#8220;mCRC&#8221;), who have a KRAS mutation.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development of onvansertib, as part of a combination regimen with already approved drugs, has the potential to bring new treatment options to patients across a wide array of cancers. Onvansertib has shown preclinical antitumor activity as a single agent and synergy (interaction of discrete drugs such that the total effect is greater than the sum of the individual effects) in combination with numerous different chemotherapeutics and targeted therapies, such as Zytiga&#174;&#160;(abiraterone acetate), Avastin&#174;&#160;(bevacizumab), Camptosa&#174;&#160;(irinotecan), Gemzar&#174;&#160;(gemcitabine), Beleodaq&#174;&#160;(belinostat), Venclexta&#174;(venetoclax), quizartinib&#160;(AC220), a development stage FLT3 inhibitor, Taxol&#174;&#160;(paclitaxel), and Velcade&#174;&#160;(bortezomib) in AML, mCRPC, mCRC and other hematologic and solid tumor cancers.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August&#160;16, 2017, we announced results of preclinical research indicating potential synergy of onvansertib with an investigational FLT3 Inhibitor, quizartinib by Daiichi Sankyo, in FLT3 mutant xenograft mouse models. This synergy assessment study was conducted for us by a third-party contract research group. Approximately one third of AML patients</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">harbor FLT3-mutated blood cancer cells. In the fourth quarter of 2018, the FDA approved Xospata (gilteritinib) by Astellas, which joins Rydapt&#174;&#160;(midostaurin) by Novartis for the treatment of adult patients with AML that are FLT3 mutation-positive. A third FLT3 inhibitor, quizartinib by Daiichi Sankyo, is currently under review by the FDA. We believe that a combination of </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">onvansertib with a FLT3 inhibitor for AML patients with a FLT3 mutation could extend treatment response and possibly slow or reduce resistance to FLT3 activity.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August&#160;21, 2017, we announced results of preclinical research indicating potential synergy of onvansertib with a histone deacetylase (&#8220;HDAC&#8221;) inhibitor in&#160;Non-Hodgkin&#160;Lymphoma (&#8220;NHL&#8221;) cell lines. This synergy assessment study was conducted by Dr.&#160;Steven Grant, Associate Director for Translational Research and&#160;co-Leader,&#160;Developmental Therapeutics Program, Massey Cancer Center. Patients with relapsed or refractory NHL, such as cutaneous T-cell lymphoma and peripheral T-cell lymphoma, may be prescribed approved HDAC inhibitors and we believe this continues to be an area of unmet medical need. Dr.&#160;Grant&#8217;s data appeared to indicate that the combination of onvansertib with Beleodaq&#174;&#160;(belinostat), an HDAC inhibitor indicated for the treatment of patients with relapsed or refractory peripheral&#160;T-cell&#160;lymphoma, reduced cancer cells by up to 80% in two different forms of NHL (aggressive&#160;double-hit&#160;B-cell&#160;lymphoma and mantle cell lymphoma) cell lines.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October&#160;18, 2017, we announced results of preclinical research indicating potential synergy of onvansertib with abiraterone acetate in&#160;C4-2&#160;prostate cancer cells. This synergy assessment study was conducted by Dr.&#160;Michael Yaffe M.D., Ph.D. FACS, David H. Koch Professor of Biology and Biological Engineering at Massachusetts Institute of Technology (&#8220;MIT&#8221;). The results appeared to indicate that the combination of onvansertib with Zytiga&#174;&#160;(abiraterone) decreased cell viability in mCRPC tumor cells and the apparent synergy observed was greater than the expected effect of combining the two drugs. Zytiga&#174;&#160;is indicated for use in combination with prednisone for the treatment of patients with mCRPC who have received prior chemotherapy containing docetaxel. We believe there is an unmet medical need to improve on the resistance to hormone therapy and extend the benefit of response to abiraterone for mCRPC patients.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategy includes integrating a predictive clinical biomarker approach into our onvansertib clinical development program, which we believe may enable us to tailor treatment to specific&#160;sub-populations&#160;of patients who are most likely to respond and have a positive clinical impact. PLK1 uniquely phosphorylates translational control tumor protein (&#8220;TCTP&#8221;) to form pTCTP and inhibition of this enzymatic activity by onvansertib appears to be predictive of patient response to treatment.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Onvansertib Phase 1 Safety Study in Solid Tumors</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A Phase 1 safety study of onvansertib was completed in patients with advanced metastatic solid tumor cancers and published in July, 2017, in the peer-reviewed journal </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investigational New Drugs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Dr.&#160;Glen Weiss, Medical Oncologist at Goodyear, AZ and affiliated with Cancer Treatment Centers of America at Western Regional Medical Center, was the principal investigator and first author of the publication, entitled &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Phase 1 Dose-Escalation Study of&#160;NMS-1286937,&#160;an Orally Available Polo-like Kinase 1 Inhibitor, in Patients with Advanced or Metastatic Solid Tumors.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; This study evaluated first-cycle dose limiting toxicities and related maximum tolerated dose with data indicating a manageable safety profile for onvansertib (also known as&#160;PCM-075&#160;and&#160;NMS-1286937)&#160;for the treatment of advanced or metastatic solid tumors, with transient adverse events that were likely related to the drug&#8217;s mechanism of action. The authors believe that data from preclinical work, coupled with the results of the Phase 1 trial, suggest that onvansertib could become a new therapeutic option for the treatment of solid tumor and hematologic cancers.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In this trial, onvansertib was administered orally, once daily for five consecutive days, every three weeks, to evaluate first cycle dose-limiting toxicities and related maximum tolerated dose in adult subjects with advanced&#47;metastatic solid tumors. The study was also intended to evaluate onvansertib&#8217;s pharmacokinetic profile in plasma, its anti-tumor activity, and its ability to modulate intracellular targets in biopsied tissue. The study identified thrombocytopenia and neutropenia as the primary toxicities, which is consistent with the expected mechanism of action of onvansertib and results from preclinical studies. These hematologic toxicities were reversible, with recovery usually occurring within 3 weeks. No gastrointestinal disorders, mucositis, or alopecia was observed, confirming that bone marrow cells are the most sensitive to onvansertib inhibition with the applied dosing schedule.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are utilizing the existing IND applications to develop onvansertib in solid tumors as part of our clinical development expansion plans, with our initial focus in mCRPC and mCRC.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Onvansertib Phase 2 Study in metastatic Castration-Resistant Prostate Cancer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December&#160;14, 2017, we announced the submission of our Phase 2 protocol of onvansertib in combination with abiraterone acetate (Zytiga&#174;&#160;- Johnson&#160;&#38; Johnson) for the treatment of mCRPC, to the FDA and our active solid tumor IND. In</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">this multi-center, open-label, Phase 2 trial, onvansertib in combination with the standard dose of Zytiga&#174;&#160;and prednisone, all administered orally, will be evaluated for safety and efficacy. The primary efficacy endpoint is the proportion of patients achieving disease control after 12 weeks of study treatment, as defined by lack of Prostate Specific Antigen (&#8220;PSA&#8221;) </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">progression in patients who are showing signs of early progressive disease (rise in PSA but minimally symptomatic or asymptomatic) while currently receiving androgen deprivation therapy (&#8220;ADT&#8221;), abiraterone and prednisone.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This ongoing Phase 2 clinical study is being conducted at three Harvard Medical sites&#58; Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute and Massachusetts General Hospital, in Boston Massachusetts. Dr.&#160;David Einstein at the Genitourinary Oncology Program at Beth Israel Deaconess Medical Center and Harvard Medical School is the principal investigator for the Phase 2 mCRPC trial.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Onvansertib Phase 1b&#47;2 Study in metastatic Colorectal Cancer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December,&#160;2018, we submitted a new IND application and protocol for our Phase 1b&#47;2 trial of onvansertib in combination with FOLFIRI and Avastin&#174;&#160;(bevacizumab) for the second-line treatment of metastatic Colorectal Cancer with a KRAS mutation. On January&#160;16, 2019, we received notification from the FDA that the &#8220;study may proceed&#8221; and on January&#160;29, 2019, we announced an agreement with PoC Capital, LLC to fund the clinical development program. In this open-label, Phase 1b&#47;2 trial, onvansertib in combination with&#160;standard-of-care&#160;FOLFIRI and Avastin&#174;&#160;is being evaluated for safety and efficacy. The trial, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">A Phase 1b&#47;2 Study of Onvansertib&#160;(PCM-075)&#160;in Combination with FOLFIRI and Bevacizumab for&#160;Second-Line&#160;Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; will enroll up to 44 patients. We plan to conduct this trial at two prestigious cancer centers&#58; USC Norris Comprehensive Cancer Center and The Mayo Clinic Arizona, with initiation anticipated in&#160;mid-2019.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Onvansertib Phase 1b&#47;2 Study in Acute Myeloid Leukemia</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June, 2017, we announced the submission of our IND application and our Phase 1b&#47;2 protocol of onvansertib in combination with&#160;standard-of-care chemotherapy for the treatment of AML to the FDA. In July, 2017, we received notification from the FDA that our Phase 1b&#47;2 clinical trial of onvansertib in patients with AML &#8220;may proceed&#8221;. On October&#160;9, 2017, we announced that the FDA granted Orphan Drug Designation to onvansertib for the treatment of AML. We initiated our Phase 1b&#47;2 AML trial in November, 2017 and enrolled our first patient in February, 2018. On August&#160;29, 2018, we announced that the European Medicinal Agency granted Orphan Drug Designation to onvansertib for the treatment of AML in the European Union (&#8220;EU&#8221;).</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Phase 1b&#47;2 is an open-label trial to evaluate the safety and anti-leukemic activity of onvansertib in combination with&#160;standard-of-care&#160;chemotherapy in patients with AML. Phase 1b is a dose escalation trial to evaluate the safety, tolerability, dose and scheduling of onvansertib, and to determine a recommended clinical treatment dose for the Phase 2 continuation trial.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pharmacokinetics of onvansertib and correlative biomarker activity will be assessed throughout the Phase 1b and Phase 2 segments of the trial. The Phase 2 continuation trial is open-label with administration of the recommended onvansertib clinical dose in combination with&#160;standard-of-care chemotherapy to further evaluate safety and assess efficacy. Doses of onvansertib will be administered orally each day on Days&#160;1-5,&#160;in a 21 -&#160;28-daycycle in both Phase 1b and Phase 2.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have completed the first five dose escalation treatment cohorts (12&#160;mg&#47;m(2), 18&#160;mg&#47;m(2), 27&#160;mg&#47;m(2), 40 mg&#47;m(2)&#160;and 60 mg&#47;m(2)) in the Phase 1b segment of this trial. A total of nine sites are conducting this trial, which is being led by Hematologist Jorge Cortes, M.D., Deputy Department Chair, Department of Leukemia, Division of Cancer Medicine, The&#160;University of Texas&#160;MD Anderson Cancer Center and Hematologist Amer Zeidan, MBBS, MHS, assistant professor of Medicine at&#160;Yale School of Medicine, Hematology expert at Yale Cancer Center.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Optimizing Drug Development with Correlative Biomarker Analysis using Circulating Tumor DNA</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have significant experience and expertise with biomarkers and technology in cancer, including AML. We are using our Precision Cancer Medicine (&#8220;PCM</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) technology to measure PLK1 enzymatic activity to potentially identify patients most likely to respond to onvansertib and to measure patient therapy response. The TCTP is phosphorylated by PLK1 at residue serine 46 (pTCTP) and has been shown to be a specific marker of PLK1 activity&#160;in-vivo&#160;in preclinical models. In our ongoing clinical trial in AML, we validated that pTCTP and TCTP are present and can be detected by capillary Western-Blot (&#8220;WB&#8221;) in peripheral blood mononuclear cells (&#8220;PBMC&#8221;) isolated from healthy donors and AML patients,&#160;24-hours&#160;after blood collection. As an exploratory objective of the Phase 1b segment of the trial, we are assessing the extent of PLK1 inhibition by</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">onvansertib in patients receiving treatment and plan to use this information and methodology going forward in the Phase 2 continuation trial, and beyond.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Technological advancements in the molecular characterization of cancers have enabled researchers to identify an increasing number of key molecular drivers of cancer progression. These discoveries have led to multiple novel anticancer </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">therapeutics and clinical benefit in selected patient populations.&#160;As a clinical-stage oncology therapeutics company developing targeted therapies to treat leukemias, lymphomas and solid tumor cancers, our objective is to optimize drug development by using our proprietary PCM&#174;&#160;expertise and biomarker strategy as part of our approach.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our laboratory in San Diego, California, enables us to use our technology platform to optimize drug development and patient care. In the clinical development of our drug candidate, onvansertib, correlative biomarker analysis are being used to help inform decisions in the evaluation of dose-response and optimal regimen for desired pharmacologic effect and safety. Additionally, some biomarkers can be used as a surrogate endpoint for efficacy and&#47;or toxicity, as well as predicting patients&#8217; response by identifying certain patient populations that are more likely to respond to the drug therapy.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating Segment and Geographic Information</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate in one business segment, using one measurement of profitability to manage our business. We do not assess the performance of our geographic regions on measures of revenue or comprehensive income or expense. In addition, all of our principal operations, assets and decision-making functions are located in the U.S. We do not produce reports for, or measure the performance of, our geographic regions on any asset-based metrics. Therefore, geographic information is not presented for revenues or long-lived assets.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Company Information</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in the State of Florida on April&#160;26, 2002. On July&#160;2, 2004, we acquired Xenomics, a California corporation, which was in business to develop and commercialize urine-based molecular diagnostics technology. In 2007, we changed our fiscal year end from January&#160;31 to December&#160;31 and in January&#160;2010, we&#160;re-domesticated&#160;our&#160;state&#160;of&#160;incorporation from Florida to Delaware and our name was changed to Trovagene,&#160;Inc. We have trademarks for the name TROVAGENE, TROVAGENE PRECISION CANCER MEDICINE and TROVAGENE ONCOLOGY. Our principal executive offices are located at 11055 Flintkote Avenue, San Diego, CA 92121, and our telephone&#160;number&#160;is&#160;858-952-7570.&#160;Our&#160;website&#160;address is</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;www.trovageneoncology.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The information on our website is not part of this prospectus supplement. We have included our website address as a factual reference and do not intend it to be an active link to our website.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The Securities We May&#160;Offer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, either individually or in units, from time to time under this prospectus, together with any applicable prospectus supplement and related free writing prospectus, at prices and on terms to be determined by market conditions at the time of offering. If we issue any debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of the debt securities. Each time we offer securities under this prospectus, we will provide offerees with a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities being offered, including, to the extent applicable&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> designation or classification&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> aggregate principal amount or aggregate offering price&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> maturity, if applicable&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> original issue discount, if any&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> rates and times of payment of interest or dividends, if any&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> redemption, conversion, exchange or sinking fund terms, if any&#59;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> ranking&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> restrictive covenants, if any&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> voting or other rights, if any&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> important United States federal income tax considerations.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update, or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may sell the securities to or through underwriters, dealers or agents or directly to purchasers. We, as well as any agents acting on our behalf, reserve the sole right to accept and to reject in whole or in part any proposed purchase of securities. Each prospectus supplement will set forth the names of any underwriters, dealers or agents involved in the sale of securities described in that prospectus supplement and any applicable fee, commission or discount arrangements with them, details regarding any over-allotment option granted to them, and net proceeds to us. The following is a summary of the securities we may offer with this prospectus.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have authorized 150,000,000 shares of common stock, par value $0.0001 per share. As of June&#160;24, 2019, 5,441,363 shares of common stock were issued and outstanding.&#160; We may offer shares of our common stock either alone or underlying other registered securities convertible into or exercisable for our common stock. Holders of our common stock are entitled to such dividends as our board of directors (the &#8220;Board of Directors&#8221; or &#8220;Board&#8221;) may declare from time to time out of legally available funds, subject to the preferential rights of the holders of any shares of our preferred stock that are outstanding or that we may issue in the future. Currently, we do not pay any dividends on our common stock. Each holder of our common stock is entitled to one vote per share. In this prospectus, we provide a general description of, among other things, the rights and restrictions that apply to holders of our common stock.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have authorized 20,000,000 shares of preferred stock, par value $0.001.&#160; 277,100 shares are designated as Series&#160;A Convertible Preferred Stock, of which 60,600 shares are outstanding as of June&#160;24, 2019, 8,860 shares are designated as Series&#160;B Convertible Preferred Stock, none of which are outstanding as of June&#160;24, 2019 and 200,000 shares are designated as Series&#160;C Convertible Preferred Stock, none of which are outstanding as of June&#160;24, 2019.&#160; Any authorized and undesignated shares of preferred stock may be issued from time to time in one or more additional series pursuant to a resolution or resolutions providing for such issue duly adopted by our Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of preferred stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The rights, preferences, privileges, and restrictions granted to or imposed upon any series of preferred stock that we offer and sell under this prospectus and applicable prospectus supplements will be set forth in a certificate of designation relating to the series. We will incorporate by reference into the registration statement of which this prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of shares of that series of preferred stock. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Debt Securities</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may offer general debt obligations, which may be secured or unsecured, senior or subordinated, and convertible into shares of our common stock. In this prospectus, we refer to the senior debt securities and the subordinated debt securities together as the &#8220;debt securities.&#8221; We may issue debt securities under a note purchase agreement or under an indenture to be entered between us and a trustee and forms of the senior and subordinated indentures are included as an exhibit to the registration statement of which this prospectus is a part. The indentures do not limit the amount of securities that may be issued under it and provides that debt securities may be issued in one or more series. The senior debt securities will have the same rank as all of our other indebtedness that is not subordinated. The subordinated debt securities will be subordinated to our senior debt on terms set forth in the applicable prospectus supplement. In addition, the subordinated debt securities will be effectively </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">subordinated to creditors and preferred stockholders of our subsidiaries. Our Board of Directors will determine the terms of each series of debt securities being offered. This prospectus contains only general terms and provisions of the debt securities. The applicable prospectus supplement will describe the particular terms of the debt securities offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of debt securities being offered, as well as the complete note agreements and&#47;or indentures that contain the terms of the debt securities. Forms of indentures have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of debt securities being offered will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may offer warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue the warrants by themselves or together with common stock, preferred stock or debt securities, and the warrants may be attached to or separate from any offered securities. Any warrants issued under this prospectus may be evidenced by warrant certificates.&#160; Warrants may be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. Our Board of Directors will determine the terms of the warrants. This prospectus contains only general terms and provisions of the warrants. The applicable prospectus supplement will describe the particular terms of the warrants being offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of warrants being offered, as well as the complete warrant agreements that contain the terms of the warrants. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Units</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may offer units consisting of our common stock or preferred stock, debt securities and&#47;or warrants to purchase any of these securities in one or more series. We may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular series of units. This prospectus contains only a summary of certain general features of the units. The applicable prospectus supplement will describe the particular features of the units being offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_58"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RISK FACTORS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An investment in our securities involves a high degree of risk. This prospectus contains, and the prospectus supplement applicable to each offering of our securities will contain, a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; in this prospectus and the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under Item&#160;1A, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#8221; in our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2018, filed with the SEC on March&#160;6, 2019, and any updates described in our Quarterly Reports on Form&#160;10-Q, all of which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in the offered securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div id="if198fbfccf55490aa8d53f15a6567c71_61"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FORWARD-LOOKING STATEMENTS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus and any accompanying prospectus supplement, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Any statements in this prospectus and any accompanying prospectus supplement about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8220;intend,&#8221; &#8220;plan,&#8221; and &#8220;would.&#8221; For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should read this prospectus and any accompanying prospectus supplement and the documents that we reference herein and therein and have filed as exhibits to the registration statement, of which this prospectus is part, completely and with the understanding that our actual future results may be materially different from what we expect.&#160; You should assume that the information appearing in this prospectus and any accompanying prospectus supplement is accurate as of the date on the front cover of this prospectus or such prospectus supplement only.&#160; Because the risk factors referred to on page&#160;9 of this prospectus and incorporated herein by reference, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. &#160;Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.&#160; New factors emerge from time to time, and it is not possible for us to predict which factors will arise.&#160; In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.&#160; We qualify all of the information presented in this prospectus and any accompanying prospectus supplement, and particularly our forward-looking statements, by these cautionary statements.</font></div><div style="text-indent:36pt;"><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_64"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">USE OF PROCEEDS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as described in any prospectus supplement and any free writing prospectus in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered under this prospectus for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. We may also use the net proceeds to repay any debts and&#47;or invest in or acquire complementary businesses, products, or technologies, although we have no current commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus. We have not determined the amount of net proceeds to be used specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of the net proceeds and investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of the securities. Pending use of the net proceeds, we intend to invest the proceeds in short-term, investment-grade, interest-bearing instruments.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each time we offer securities under this prospectus, we will describe the intended use of the net proceeds from that offering in the applicable prospectus supplement. The actual amount of net proceeds we spend on a particular use will depend on many factors, including, our future capital expenditures, the amount of cash required by our operations, and our future revenue growth, if any. Therefore, we will retain broad discretion in the use of the net proceeds.</font></div><div style="text-indent:36pt;"><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_67"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF CAPITAL STOCK</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following description of our capital stock, together with any additional information we include in any applicable prospectus supplement or any related free writing prospectus, summarizes the material terms and provisions of our common stock and the preferred stock that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will describe the particular terms of any class or series of these securities in more detail in the applicable prospectus supplement. For the complete terms of our common stock and preferred stock, please refer to our amended and restated certificate of incorporation, as amended and our bylaws that are incorporated by reference into the registration statement of which this prospectus is a part or may be incorporated by reference in this prospectus or any applicable prospectus supplement. The terms of these securities may also be affected by Delaware General Corporation Law (the &#8220;DGCL&#8221;). The summary below and that contained in any applicable prospectus supplement or any related free writing prospectus are qualified in their entirety by reference to our amended and restated certificate of incorporation, as amended, and our bylaws.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of the date of this prospectus, our authorized capital stock consisted of 150,000,000&#160;shares of common stock, $0.0001 par value per share, and 20,000,000&#160;shares of preferred stock, $0.001 par value per share. Our Board may establish the </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">rights and preferences of the preferred stock from time to time. As of June&#160;24, 2019, there were 5,441,363 shares of our common stock issued and outstanding and 60,600 shares of Series&#160;A Convertible Preferred Stock are issued and outstanding.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are authorized to issue up to a total of 150,000,000 shares of common stock, par value $0.0001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. All shares of common stock offered hereby will, when issued, be fully paid and nonassessable, including shares of common stock issued upon the exercise of common stock warrants or subscription rights, if any.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, holders of our common stock have no preemptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or winding- up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our Board of Directors out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:20.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of a majority of the shares of our capital stock, represented in person or by proxy, are necessary to constitute a quorum for the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of the election of directors, which requires a plurality of the votes cast.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our board of directors has the authority, without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock. Our board of directors, without stockholder approval, can issue convertible preferred stock with voting, conversion, or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting and other rights of the holders of common stock. At present, we have no plans to issue any shares of preferred stock following this offering.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Anti-Takeover Effects of Certain Provisions of our Certificate of Incorporation, Bylaws and the DGCL</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:20.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly traded Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business combination includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An interested stockholder is a person who, together with affiliates and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">associates, owns (or within three years, did own) 15% or more of the corporation&#8217;s voting stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing a change in control of our company.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated certificate of incorporation, as amended, and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. In particular, the certificate of incorporation and bylaws, as applicable, among other things&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> provide our board of directors with the ability to alter our bylaws without stockholder approval&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> provide that vacancies on our board of directors may be filled by a majority of directors in office, although less than a quorum.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Such provisions may have the effect of discouraging a third-party from acquiring us, even if doing so would be beneficial to our stockholders. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by them, and to discourage some types of transactions that may involve an </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">actual or threatened change in control of our Company. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage some tactics that may be used in proxy fights. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our Company outweigh the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could result in an improvement of their terms.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, these provisions could have the effect of discouraging others from making tender offers for our shares that could result from actual or rumored takeover attempts. These provisions also may have the effect of preventing changes in our management.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:2.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Listing</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:31.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is listed on The Nasdaq Capital Market under the trading symbol &#8220;TROV.&#8221;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:2.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Transfer Agent and Registrar</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Transfer Agent and Registrar for our common stock is Philadelphia Stock Transfer,&#160;Inc.</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_70"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF DEBT SECURITIES</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following description, together with the additional information we include in any applicable prospectus supplements or free writing prospectuses, summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. We may issue debt securities, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below. However, no prospectus supplement shall fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. As of the date of this prospectus, we have no outstanding registered debt securities. Unless the context requires otherwise, whenever we refer to the &#8220;indentures,&#8221; we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the subordinated indenture and any supplemental indentures that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The indentures will be qualified under the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;). We use the term &#8220;trustee&#8221; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all of the provisions of the indenture and any supplemental indentures applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indentures that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of each series of debt securities will be established by or pursuant to a resolution of our Board of Directors and set forth or determined in the manner provided in an officers&#8217; certificate or by a supplemental indenture. Debt securities may be issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series. We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the title&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any limit on the amount that may be issued&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depositary will be&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the maturity date&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> whether or not the debt securities will be secured or unsecured, and the terms of any secured debt&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the terms of the subordination of any series of subordinated debt&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the place where payments will be made&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> restrictions on transfer, sale or other assignment, if any&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> our right, if any, to defer payment of interest and the maximum length of any such deferral period&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> provisions for a sinking fund purchase or other analogous fund, if any, including the date, if any, on which, and the price at which we are obligated, pursuant thereto or otherwise, to redeem, or at the holder&#8217;s option, to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> whether the indenture will restrict our ability or the ability of our subsidiaries, if any, to&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> incur additional indebtedness&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> issue additional securities&#59;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> create liens&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> redeem capital stock&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> place restrictions on our subsidiaries&#8217; ability to pay dividends, make distributions or transfer assets&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> make investments or other restricted payments&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> sell or otherwise dispose of assets&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> enter into sale-leaseback transactions&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> engage in transactions with stockholders or affiliates&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> issue or sell stock of our subsidiaries&#59; or</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:94.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> effect a consolidation or merger&#59;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> a discussion of certain material or special United States federal income tax considerations applicable to the debt securities&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> information describing any book-entry features&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the applicability of the provisions in the indenture on discharge&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> whether the debt securities are to be offered at a price such that they will be deemed to be offered at an &#8220;original issue discount&#8221; as defined in paragraph (a)&#160;of Section&#160;1273 of the Internal Revenue Code of 1986, as amended&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Conversion or Exchange Rights</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will set forth in the applicable prospectus supplement the terms under which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third party) that the holders of the series of debt securities receive would be subject to adjustment.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidation, Merger or Sale</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are convertible into or exchangeable for our other securities or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Events of Default under the Indenture</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if specified events of bankruptcy, insolvency or reorganization occur.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will describe in each applicable prospectus supplement any additional events of default relating to the relevant series of debt securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default arises due to the occurrence of certain specified bankruptcy, insolvency or reorganization events, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the direction so given by the holder is not in conflict with any law or the applicable indenture&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The indentures will provide that if an event of default has occurred and is continuing, the trustee will be required in the exercise of its powers to use the degree of care that a prudent person would use in the conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with law or the indenture, or that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant series of debt securities, or that would involve the trustee in personal</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">liability. Prior to taking any action under the indentures, the trustee will be entitled to indemnification against all costs, expenses and liabilities that would be incurred by taking or not taking such action.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies only if&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the holder has given written notice to the trustee of a continuing event of default with respect to that series&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made a written request and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indentures.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The indentures will provide that if a default occurs and is continuing and is actually known to a responsible officer of the trustee, the trustee must mail to each holder notice of the default within the earlier of 90 days after it occurs and 30 days after it is known by a responsible officer of the trustee or written notice of it is received by the trustee, unless such default has been cured or waived. Except in the case of a default in the payment of principal or premium of, or interest on, any debt security or certain other defaults specified in an indenture, the trustee shall be protected in withholding such notice if and so long as the Board of Directors, the executive committee or a trust committee of directors, or responsible officers of the trustee, in good faith determine that withholding notice is in the best interests of holders of the relevant series of debt securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Modification of Indenture&#59; Waiver</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific matters&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to fix any ambiguity, defect or inconsistency in the indenture&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to comply with the provisions described above under &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Description of Debt Securities &#8212; Consolidation, Merger or Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59;&#8221;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to provide for the issuance of, and establish the form and terms and conditions of, the debt securities of any series as provided under &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Description of Debt Securities &#8212; General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to evidence and provide for the acceptance of appointment hereunder by a successor trustee&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to provide for uncertificated debt securities and to make all appropriate changes for such purpose&#59;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to add such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture&#59; or</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to change anything that does not adversely affect the interests of any holder of debt securities of any series in any material respect.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may only make the following changes with the consent of each holder of any outstanding debt securities affected&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> extending the stated maturity of the series of debt securities&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities&#59; or</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:2.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Discharge</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we may elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> register the transfer or exchange of debt securities of the series&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> replace stolen, lost or mutilated debt securities of the series&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> maintain paying agencies&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> hold monies for payment in trust&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> recover excess money held by the trustee&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> compensate and indemnify the trustee&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> appoint any successor trustee.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to exercise our rights to be discharged, we will deposit with the trustee money or government obligations sufficient to pay all the principal of, and any premium and interest on, the debt securities of the series on the dates payments are due.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Form, Exchange and Transfer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures will provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a prospectus supplement with respect to that series. See &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Legal Ownership of Securities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; below for a further description of the terms relating to any book-entry securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we elect to redeem the debt securities of any series, we will not be required to&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing&#59; or</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Information Concerning the Trustee</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture and is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. However, upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Payment and Paying Agents</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest payment.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Governing Law</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Ranking Debt Securities</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The senior debt securities will be unsecured and will rank equally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_73"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF WARRANTS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue the warrants under a warrant agreement that we will enter into with a warrant agent to be selected by us. If selected, the warrant agent will act solely as an agent of ours in connection with the warrants and will not act as an agent for the holders or beneficial owners of the warrants. If applicable, we will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form&#160;8-K that we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular series of warrants that we sell under this prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will describe in the applicable prospectus supplement the terms relating to a series of warrants, including&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the offering price and aggregate number of warrants offered&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the currency for which the warrants may be purchased&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if applicable, the date on and after which the warrants and the related securities will be separately transferable&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the terms of any rights to redeem or call the warrants&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the dates on which the right to exercise the warrants will commence and expire&#59;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the manner in which the warrant agreements and warrants may be modified&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> United States federal income tax consequences of holding or exercising the warrants&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the terms of the securities issuable upon exercise of the warrants&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture&#59; or</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exercise of Warrants</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to us or the warrant agent as applicable.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Enforceability of Rights by Holders of Warrants</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If selected, each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_76"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF UNITS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the units that we may offer under this prospectus.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form&#160;8-K that we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units that we sell under this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the terms of the units.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue units comprised of one or more debt securities, shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will describe in the applicable prospectus supplement the terms of the series of units, including&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any provisions of the governing unit agreement that differ from those described below&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The provisions described in this section, as well as those described under &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Description of Capital Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#8221; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Description of Debt Securities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Description of Warrants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; will apply to each unit and to any common stock, preferred stock, debt security or warrant included in each unit, respectively.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unit Agent</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The name and address of the unit agent, if any, for any units we offer will be set forth in the applicable prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Issuance in Series</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue units in such amounts and in numerous distinct series as we determine.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Enforceability of Rights by Holders of Units</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_79"></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We, the unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. See &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Legal Ownership of Securities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LEGAL OWNERSHIP OF SECURITIES</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary or warrant agent maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Book-Entry Holders</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers&#59; they are not obligated to do so under the terms of the securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Street Name Holders</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:40.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:40.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not legal holders, of those securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Legal Holders</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Special Considerations for Indirect Holders</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> how it handles securities payments and notices&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> whether it imposes fees or charges&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> how it would handle a request for the holders&#8217; consent, if ever required&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> whether and how you can instruct it to send you securities registered in your own name so you can be a legal holder, if that is permitted in the future&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if the securities are in book-entry form, how the depositary&#8217;s rules&#160;and procedures will affect these matters.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Global Securities</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, NY, known as DTC, will be the depositary for all securities issued in book-entry form.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8220;&#8212; Special Situations When A Global Security Will Be Terminated</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Special Considerations For Global Securities</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules&#160;of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If securities are issued only as global securities, an investor should be aware of the following&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in the global security. We and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in the global security. We and the trustee also do not supervise the depositary in any way&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Special Situations When A Global Security Will Be Terminated</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A global security will terminate when the following special situations occur&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if we notify any applicable trustee that we wish to terminate that global security&#59; or</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we, nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</font></div><div><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_82"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PLAN OF DISTRIBUTION</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may sell the securities being offered hereby in one or more of the following ways from time to time&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> through agents to the public or to investors&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to underwriters for resale to the public or to investors&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> negotiated transactions&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> block trades&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> directly to investors&#59; or</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> through a combination of any of these methods of sale.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As set forth in more detail below, the securities may be distributed from time to time in one or more transactions&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> at a fixed price or prices, which may be changed&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> at market prices prevailing at the time of sale&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> at prices related to such prevailing market prices&#59; or</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> at negotiated prices.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will set forth in a prospectus supplement the terms of that particular offering of securities, including&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the name or names of any agents or underwriters&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the purchase price of the securities being offered and the proceeds we will receive from the sale&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any over-allotment options under which underwriters may purchase additional securities from us&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any initial public offering price&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any discounts or concessions allowed or re-allowed or paid to dealers&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> any securities exchanges or markets on which such securities may be listed.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Only underwriters named in an applicable prospectus supplement are underwriters of the securities offered by that prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter(s)&#160;will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. Unless otherwise</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">set&#160;forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the offered securities if any are purchased.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth in the prospectus supplement for those securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer, as principal.&#160; The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.&#160; The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may sell the securities directly or through agents we designate from time to time.&#160; We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the common stock for whom they act as agents in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any institutional investors or others that purchase common stock directly and then resell the securities, may be deemed to be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts and commissions under the Securities Act.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may provide agents and underwriters with indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may engage in at the market offerings into an existing trading market in accordance with Rule&#160;415(a)(4)&#160;under the Securities Act.&#160; In addition, we may enter into derivative transactions with third parties (including the writing of options), or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with such a transaction, the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus and the applicable prospectus supplement. If so, the third party may use securities borrowed from us or others to settle such sales and may use securities received from us to close out any related short positions. We may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement or in a post-effective amendment.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To facilitate an offering of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the market price of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons participating in the offering of more securities than have been sold to them by us. In those circumstances, such persons would cover such over-allotments or short positions by purchasing in the open market or by exercising the over-allotment option granted to those persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on the price of our securities.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_85"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is listed on The Nasdaq Capital Market. We may elect to list any other class or series of securities on any exchange or market, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to comply with the securities laws of some U.S. states or territories, if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered or licensed brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and complied with.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of these activities at any time.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any underwriters who are qualified market makers on The Nasdaq Capital Market may engage in passive market making transactions in the securities on The Nasdaq Capital Market in accordance with Rule&#160;103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security. If all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LEGAL MATTERS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The validity of the issuance of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter&#160;&#38; Hampton LLP, New York, NY.&#160; Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div id="if198fbfccf55490aa8d53f15a6567c71_88"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXPERTS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The financial statements of the Company as of December&#160;31, 2018 and 2017 and for each of the two years in the period ended December&#160;31, 2018 incorporated by reference in this Prospectus have been so incorporated in reliance on the report of BDO USA LLP, an independent registered public accounting firm (the report on the consolidated financial statements contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern) incorporated herein by reference, given upon their authority as experts in accounting and auditing.</font></div><div style="text-indent:36pt;"><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_91"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WHERE YOU CAN FIND MORE INFORMATION</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This prospectus constitutes a part of a registration statement on Form&#160;S-3 filed under the Securities Act. As permitted by the SEC&#8217;s rules, this prospectus and any prospectus supplement, which form&#160;a part of the registration statement, do not contain all the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statements made in this prospectus or any prospectus supplement concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You may read and copy the registration statement, as well as our reports, proxy statements, and other information, at the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room.&#160;The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The SEC&#8217;s</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</font></div></div></div><div id="if198fbfccf55490aa8d53f15a6567c71_94"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Internet site can be found at http&#58;&#47;&#47;www.sec.gov. You can also obtain copies of materials we file with the SEC from our website found at www.trovageneoncology.com. Information on our website does not constitute a part of, nor is it incorporated in any way, into this prospectus and should not be relied upon in connection with making an investment decision.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INCORPORATION OF DOCUMENTS BY REFERENCE</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have filed a registration statement on Form&#160;S-3 with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Act of 1933, as amended. This prospectus is part of the registration statement, however the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to &#8220;incorporate by reference&#8221; the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed. We have filed with the SEC, and hereby incorporate by reference in this prospectus&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:51.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.&#160;&#160;&#160;&#160;&#160;Our Annual Report on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828019002546/trov-123118x10k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Form&#160;10-K for the year ended December&#160;31, 2018</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, filed with the SEC on March&#160;6, 2019&#59;</font></div><div style="text-indent:51.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:51.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;&#160;&#160;&#160;&#160;Our Quarterly Report on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828019006051/trov-033119x10q.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Form 10-Q filed with the SEC on May 7, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:51.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;&#160;&#160;&#160;&#160;Our Current Reports on Form&#160;8-K filed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519009824/d611008d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">January&#160;15, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519014479/d657843d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">January&#160;23, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519021144/d692543d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">January&#160;29, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519024055/d647432d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">January&#160;31, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519035952/d706317d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">February&#160;12, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519039699/d703465d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">February&#160;14, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519044909/d711195d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">February&#160;20, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519056253/d715537d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">February&#160;28, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519062437/d717507d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">March&#160;4, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519071578/d712015d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">March&#160;12, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519073028/d712495d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">March&#160;13, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519094145/d718864d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">April&#160;1, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519095338/d688200d8k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">April&#160;2, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465919020072/a19-7895_18k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">April&#160;5, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465919023054/a19-8774_18k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">April&#160;23, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465919028892/a19-9765_38k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">May&#160;13, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465919031363/a19-10546_18k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">May&#160;23, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465919032992/a19-10903_18k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">May&#160;31, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; and </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465919034321/a19-11206_18k.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">June&#160;6, 2019</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:51.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;&#160;&#160;&#160;&#160;The description of our common stock contained in the registration statement on </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912039425/a12-9768_98a12b.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Form&#160;8-A filed with the SEC on May&#160;23, 2012</a></font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also incorporate by reference all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form&#160;8-K and exhibits filed on such form that are related to such items) that are subsequently filed by us with the U.S. Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14, or 15(d)&#160;of the Exchange Act prior to the termination of the offering of the securities made by this prospectus (including documents filed after the date of the initial Registration Statement of which this prospectus is a part and prior to the effectiveness of the Registration Statement). These documents include periodic reports, such as Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, and Current Reports on Form&#160;8-K, as well as proxy statements.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You may request, and we will provide you with, a copy of these filings, at no cost, by calling us at (858) 952-7570 or by writing to us at the following address&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Trovagene,&#160;Inc.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11055 Flintkote Avenue</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">San Diego, CA 92121</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Telephone&#58; (858)&#160;952-7570</font></div><div style="text-align:center;"><font><br></font></div><div id="if198fbfccf55490aa8d53f15a6567c71_97"></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">6,500,000 Shares of Common Stock</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><img alt="cardiff_logoxrgbxtm2.jpg" src="cardiff_logoxrgbxtm2.jpg" style="height:38px;width:250px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:103%;">PROSPECTUS SUPPLEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:88%;">Cowen</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:88%;">Piper Sandler</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:88%;">H.C. Wainwright &#38; Co.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%;">September 29, 2020</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>cardiff_logoxrgbxtm2.jpg
<TEXT>
begin 644 cardiff_logoxrgbxtm2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M Q$!_\0 Y@ !  (" @,! 0            H+" D&!P,$!0$" 0$  @(# 0$
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M,5IK?'DK:EZ6CG6U;1%JS'C$Q$ONB7'
M
M
M
M
M
M
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MJQ$1K-Z3?'$<;6K,^6-V Y+P
M
M
M
M
M
M
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M?)Y=)G.06O/
M
M
M
M
M
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M^$R[:&3I
M
M
M
M
M
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MF)XQ+WP5@
M
M
M
M
M
M                                         #5!SU]QG$;@A'M,:O,A
M_BWO"*AQJ-I37-C EW5=-[%&TG/\A/Y-/KZ&2^WR(DD_:>-9.,P'T]3*C+N,
M>+A/&WL>S^F_H7WMZC6IN]OB^Q=O3SW6>LQ2T?T-.%LT^R:Z8]8TMDK*$OSN
M]M/+GGM/GT^?9<>!::5*-RJT;KR3-J,*)AJ2V_!=R^3Y?S;85NP<=ISS6;CD
M1F2@W8<6'WJ0.MRY\F7GPK['T ].?17LGTWQUS]-P?:>O>7WMWGB+9=9C2?E
M1IY<-9UF-,<1::SI>]]-6L44O7     !_24J6I*$)-2E&24I21J4I2CZ$E)%
MU,S,S^A 3,1&L\F_;@)]O_R@Y4?D^?[W19<9=*2_C367LGJ%*VSF-<YT=(\7
MP2<J,]CT.6R7X+"[^,7:XAZ/%FMF8Y6+:WOQM[M?W6M?J5]Y;M#L[S]-[<FG
M5^OUUB8QV_[;%;^DS1K%YB>=,7FY36U\<IHW$+@9Q>X-X@>*\?-:UN/3IL9,
M?)<_MR:O-EYET6T\H\GS.2PBQE0_D,I=;@1_C5<9SJIB,UU/KV./%3%&E(_A
M:$]\>H_=_J'OOMG<^[OEQUG7'AK[F#%X?S>*)\L3I.DWGS9+1\5Y9ABQ^&
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MS,4K[<^/C;#]-I\V/PC),\&W0<AXD
M
M
M
M
M
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M ]2O7WO;U$^9L//_ ./[;MP^S8+3[]?Z?+POF^FNE,4Z1/RO-'F;@!R'AP
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M+;6<=X][%FK'.V+)'NVCC&L<+UUB+UK,Z,J!F_'
M
M
M
M
M
M
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M<*YJ1IYHY7CWZ<-:UV<"YY&
M
M
M
M
M
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M+Y$=U]M=2[.[BW?;/5Z^7?[/--+:<K1SIDKX^3)2:WIKI/EM&L1.L.[QD_/
M
M
M
M
M
M
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M3]@K;7'ML6M-OCX\-*:SY[1^7DF^33AYM.#/ 6O.
M   8/\S/7=Q4YW8NJEWSKJ+*R:'"5"QG:N+_ !L?VEB"34M;::;*D1)*IE>T
MZXI?Y=9,SZM:U&M48UDE159,./+&EHX^WQ>A=A^J'>7ISO/M';>ZM7:6MKDV
M^36^WR_QL>L:6\//CFF33A%]."%=S^]#7*OA]^=9]J^-+Y*:(AG*FN91A-+)
M3L+#:MEHY2W,^UY%783DP8+"7/):U3D^ EIA3\HH!+0R.NR[7)CXUXU;\^FO
MWCNS>^/E]-ZO->D]QVTCY>6\?)RVGA_,YYTC69TTQY(I?6?+3YFDV:+QQFQ
M   "6W]L)RZ?K\HW!PJRJU=56Y%!=W5J5B4\DV8E]4I@4NR,?@^3N>-VZIEU
MUFRPCM:;*KFN].]U1JY^RR<9QS]<?OM*?O==D5R[/8]_;.D?-Q6C:[F8CC-+
M:WP7GP]RWGQS,\9^9CKRK&DR8=@T2
M
M
M
M
M
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M?AP
M
M
M
M
M
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M[[K<VM?<9;VO>TSK-K6F9M:9\9F9F9GVOJ I
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MT1:/&(:C]:Z%UCMW?6Z9US;9=KOJ<ZWKIK'MK/*U9\+5F:SX3+DP[AU(
M
M
M
M
M
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MK
M
M
M
M
M                                                       !3_#H
M'W#  !DAPW_PO.*W^4AH[^Z=BXSQ_I*_7'X7Y7OK_1'6?_5;O_#Y%KB.\?&8
M                              %5_P"PK_#[YQ?Y8')?^[1FHZ3+^EM_
M&G\+[%^F/^VO;W_H]A_A<3#X5OW   +='7G_ # P;^P_&?ZRPAWT<H^I\2NJ
M?YGN/U^3^7+F EP0   '6^R=MX!J6I_-LXR"+5I=0X<"M1_55U;.-I,S:K*M
MGNE2?Q=$J<,DL-*47D6@CZC\AWAWYVMV)L/M_<N[I@BT3Y,<>]FRS'ACQQ[U
MN.D3;2*5F8\]JQ.K]5VIV5W+WKO?L7;VVOFFLQY\D^[BQQ/CDR3[M?&8KQO:
M(GRUM,:-4^Z.;>>Y^4NDP1,C ,5=)32WXLCKE=DR?T/Y5JP9)JFW"+ZM1#)9
M$9I4\XD^@T=]1/O(=T=T_,Z;VQ%^E=$MP\U;?]SDC\[+7]%$_DXN,<8G):)T
M;E=A?=^[;[:\G4.XYKU/K->.EJ_]OCG\W'/Z28_*R<.4QCK+"1:U.*4M:E+6
MM1K6M9FI2U*,S4I2C,S4I1GU,S^IF-<+6M:TVM,S:9UF9YS+8&(BL16L1%8C
MA#\$)    =RZHT)LS<DE2,.HS*J9<-F9DUNMRNQR&X234;2Y_A><ER$_3N9B
MMR'D$I)J023[AZ%V-Z7=Y>H6::]O[;_L:SI?<99G'MZ3[)OI,VMRUICK>\:Q
M,UB)U?A.\_4GM+L3#$]=W'_>6C6N#%$7SVCVQ36(K7GI;):E9TF(M,\'9.S>
M&VX];URKI,&OS2G91Y)LG#USI\RN07\YR94RH,.Q4PGH9J<80^VV@NYPT$/V
M'>7W>_4'M#:3U&N+%U'I]8UO;:3>]\<>V^*U*9-/&;4K>M8XVFK\IVEZ[=B]
MU[J-A.3+L-]:=*UW,4I6_P!%<E;VIKX16\TM,\*Q9BB/#7LP     [ZT_P C
M]FZ9?98Q^V.SQGS>25B-VIV72N)6ON?5!3WID4\ISN,_)&4@E+Z&XAPB[3]0
M[ ]7N\O3S+7%TK/\[HWFUMM<VML,ZSK::<?-BM/&?-CF(F=)O6\1H\W[X]*^
MTN_,=LG4\/R>K>72NYQ:5RQI'"+\/+EK'+RWB=(UBDTF=6VG2_*K6FXBC5;4
MO]*YDXE)+Q:\?:0Y+>/Z&FAL?W4:Z+K]2;23<GH1F;))+J-[?3OUO[.]0(IL
MJ9/L/<-HC7;9K1$VGV8<G"N;Z*QY<FFLSCB(U:5]^^C?=G8LWW=Z?;.A1/#<
M8HF8K']-3C;%]<^;'KPB\S.C)D>R/)0
M
M
M
M
M
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M4CG;-ACPI'/)CCA6-;4TI$UC9<-QFIH
M
M
M
M
M
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MSKVM/TM0.X.YNN]U;^>I=P;G+N=W.NDVGW:Q/XM*1I2E?S:5B/H<Q'Z!T0
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M#UC[(IV1WEEVVSKY>C;N/GX.'"M;3,7Q1^KO$Q$<XI-)GFR3'L#RD
M
M
M
M
M
M                                           %/\.@?<,  &2'#?\
MPO.*W^4AH[^Z=BXSQ_I*_7'X7Y7OK_1'6?\ U6[_ ,/D6N([Q\9@
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MN'URW!#?UHX
M
M
M
M
M
M "G^'0/N&  #)#AO_A><5O\ *0T=_=.Q<9X_TE?KC\+\KWU_HCK/_JMW_A\B
MUQ'>/C,                              "J_]A7^'WSB_P L#DO_ ':,
MU'29?TMOXT_A?8OTQ_VU[>_]'L/\+B8?"M^X  !;HZ\_Y@8-_8?C/]980[Z.
M4?4^)75/\SW'Z_)_+ES 2X( UT^Q4S_1>N2ZGT/*+4S+^0S*I3T/I_LEU/\
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ML59GG%*WF:QK[*^;RQ[*Q$1PAB:/"GM( RRX2?X1.)?\697_ -&[(>Z_=O\
M]V=A^IW/^'R/%OO _P"U^]_7;?\ KZ-Y0^ECYY
M
M
M
M
M
M                             I_AT#[A@  R0X;_ .%YQ6_RD-'?W3L7
M&>/])7ZX_"_*]]?Z(ZS_ .JW?^'R+7$=X^,P
M      *K_P!A7^'WSB_RP.2_]VC-1TF7]+;^-/X7V+],?]M>WO\ T>P_PN)A
M\*W[@  %NCKS_F!@W]A^,_UEA#OHY1]3XE=4_P SW'Z_)_+ES 2X( UT>Q7_
M )EZY_LGM?ZU(&I/WMO].](_ON7^J;2?=<_S[JO]SQ_UDM30T4;I #Z=)_[Y
MJ/\ C.!_OIH<WIO^8[?]=3^5#B=0_L&?]3?^3*32/LH^2@
M-)/.O_K^L?[&,:_WL\/G!]YK_=++_<MO_)E] ?NZ_P"VN+^^9_Y4,.1KZ]U
M&67"3_")Q+_BS*_^C=D/=?NW_P"[.P_4[G_#Y'BWW@?]K][^NV_]?1O*'TL?
M/(
M
M
M
M
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M'R/%OO _[7[W]=M_Z^C>4/I8^>0
M
M
M
M
M
M                 *?X= ^X8  ,D.&_^%YQ6_RD-'?W3L7&>/\ 25^N/POR
MO?7^B.L_^JW?^'R+7$=X^,P                              *K_ -A7
M^'WSB_RP.2_]VC-1TF7]+;^-/X7V+],?]M>WO_1[#_"XF'PK?N   6Z.O/\
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MSR
M
M
M
M
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M (?(\6^\#_M?O?UVW_KZ-Y0^ECYY
M
M
M
M
M
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MG$O^+,K_ .C=D/=?NW_[L[#]3N?\/D>+?>!_VOWOZ[;_ -?1O*'TL?/(
M
M
M
M
M
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MW_[L[#]3N?\ #Y'BWW@?]K][^NV_]?1O*'TL?/(
M
M
M
M
M
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MWF^QUT\9ICBV2T_5%JTB?IM#<X/H<T-
M
M
M
M
M
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MPT[W_3]_TK>9.G]3PY=OO\5O+?'DK:EZ6CPM6T1,3]<.4B7#
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M66\70>@=%[8Z7BZ+T#;8MITO#&E<>.-(X\YF9UFUK3QM>TS:T\;3,\75PAW
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M.9B9B89E#81X0
M
M
M
M
M
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M0B(A]"XB*QY:\(AH?,S,ZSQF7Z)0
M
M
M
M
M
M                    CE>[_P!/KO+NEE<G^-]"R?)C%*J+&S##H9PX2-W8
MC41C9CDRIQ#+;FR\;A-MM0''74_F->T4)1J<:ADGB;G;_,CST^/\/_%M-]WS
MUQCLC<5[0[JR3_\ 4LUYG%EG6?LF2TZSKS_F,DZS>(CW+S\R-(G)K!"M:JTH
MK2RI+NMGT]U3SYE5;U%K#D5]I56E?(<B3ZVR@2VV9<&?!ELK:>9=0EQIQ)I4
M1&1D.KY<)YOHSAS8=SAIN-O>N3;Y*Q:MJS%JVK:-:VK:-8F)B8F)B=)CC#T
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MCA$1'"(CA$-9\F2^6]LN6TVR6F9F9G69F>,S,SQF9GC,SS>09L
M
M
M
M
M
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MA6/R:5C2M*^RM(K7Z'+1WKI0
M
M
M
M
M
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M]2^Z^_,\SUG/->GQ;6FWQZUPT]GNZS-[1^7DFUN>DQ'!W4/1GX
M
M
M
M
M
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M!YEZ@^D?97J3MYCKNV\G5(KI3=8=*;BFG*)OI,9*1Q]S+6]8UF:Q6VEHFP\
M_=YQ*YN?D^$W-DC0&^9WQHB=7;#N87Y5DUH]T3\?6V>*:KJG+5N.J2AJ%(9K
M;AU9GXX;B$&Z?98MSCR<.5O8T!]2ON^]Z^GWS.H8*?\ D^VZZS]HP5GS8ZQX
MY\/O6Q^V;5G)BB.>2)G1N8'(>#@#3YS[]U7$C@TBXPYJX1O/?<#NCIT_KNVA
MK103R-PC:V3FR6;&EP;PFV9.0_'.NDFMM7P/"YYD\?+N<>+ASO[/X7N7IKZ!
M=[>H<X]_./\ \=VW;C]ISUGWX_H,6M;YM?"VM,7"8^9YH\LPF^<?M,Y;\][5
M^/M?-OTWK!F8<FCTK@!S*#7=:3;A+B/VT0Y3]CF=PQV$HIEL_+4TX:SC(C-J
M\1=;ESY,OQ3[OL;_ 'IYZ/=D^F^&+=%V_P WJ\UTONLVE\]O;%9TBN*L_DXX
MKK&GGF\QJURBIZF     /-'CR)<AB)$8>E2I3S4>-&CM+>D2)#RTMLL,,MI4
MXZ\ZXHDI2DC4I1D1%U!C:U:5F]YB*1&LS/"(B.<S/A$)#/ /[>?DCR2.CV%R
M:=M>,^FI?Q9[=+8P&CWAF%<XLU*:J<1L6EQ\ 9D--J24R_;*4T:FW&ZR4TON
M+EXMI>_&_NU_=:Q>I7WG>U.U/F=,[2BG5NO5UCSUG_M,5OSLE>.:8_)PSY9X
MQ.:EHT3-^*7"?C/PJPL\*X[ZOI,+:F,QD9'E+B#ML\S-^,1FB7EV9V'FO+GM
M?6XXU&-U$"&IU916&$*[!V./'3'&E(T:&]Y^H'=O?^__ /(=T;S)N)K,^3'\
M.'%$^&+%72E>&D3;2;VTCSVM/%E6,WXT   !K^YJ>SCB!P,K5)WAL9N3GC\1
MF94:>P5$/*-J6T>22CBRSQQ,^%&Q^KDI0HVIMO)KH;W8I+3JUEV'=BV^7-\$
M</;X/Q?=??\ VQV=C_\ Y?/KO)C6N#'I?-:)Y3Y=8BL3X6O-:SX3,\$7'D5]
MT)R5R^985G&G3>NM-XXI2VH619VN;L_/EH3WI;G--)7CN%5#KY&2E1G:^U2T
M9=I/K+ZGV-.GXX_23,S^U#7KKGW@^O;JUL?0-K@VN#PMDURY/K_%QU^J:WT]
MLM7N7>Z3V@YI*D2K3E]L*N.0F0@V,1JL(P:*RW(0EM2(\?#L5HT,J:0@B;<+
M]ZV?51*)9J4?(C:[>.58_"\]W/JKZ@[NTVR=3SUUU^",>../L\E*_L>/[+YN
M+^Y#V=8@_"D57,;:DMR 2$L)R@L8S=A9(=0\GYL7-,=OXUD9K;(C.0ATU(ZI
M/JDS(T[7;S^+##;^J/J!M9BV/JFYF8_+\F3]N,E;1/[.OLY-D7'[[G/F1@4R
M!"W[KS5N_L;0MLK&? @/:IV"\CM0VMR/<XXBPP=/0B-SQGCJ36L^A.(3T[:+
M]/Q6^"9K/[<?_/V7[OHOK_W3L[5IUK!M][@\9B/DY/V+5UQ_3I\K]F$GO@[[
M?^%_.YV%C&O<VDZ_V](9)2M,[517XSFD]YMI3DDL0DLV$_'<[9033KA-UDQZ
M>B,V;TB)'3U(NOS;7+AXVC6OMAL#VCZG=J]X3&WV6:</4YC]!FTI>?;Y)UFN
M3QGW+3;2-;5JVC#CO0@    !TUMG0NM=RPO%EU*E-LTR;4#)ZHVX.10"Z?@2
MB<33B)D=OJ?1B4A]@C,S)!*^H\\[Z]+^S_4+;^3KVVB-_6NE-SBTIGI[-+Z3
M%ZQX4R5O2-9F*Q/%^\[+]2.Z^Q-QY^B;B9V4VUOM\FM\%_;K36)K:?&^.:7G
MA$VF.#5ULW@WMK#7Y$K$&V-B4*34MMVJ\4&_9:^ID4NBER.Y]POH1%#=DJ5U
MZ]J?J1:5]Y?=J[[[>R6S] BO5NF1QB<6E,\1^=AM;C/A_-6R3//2.4;?=I?>
M&[*Z[CKAZY-NE]1GA,9-;X9G\W-6O"/'^=KCB.6L^.)5WBV3XT\J/D>.7U!(
M0KL4Q=U%A5/)674NQ34Z.PLE=2/Z=.OT'A'4NB=9Z/DG%U?:;K:Y8G33-BR8
MIU]FEZUG5[7T_K'2.K4C+TK=;;<XYC77%EIDC3VZTM,/F0X,ZQ?3&KX<J=)5
M]4QX<=Z4^HNY*.J6F$+</\2B+]G[3(</;[7<[O+&':8[Y<T_BTK-K>SE$3/.
M8<O/N=OM<?SMUDICQ1^-:T5CV\YF(9"8#Q0WCG[S)QL-FXU6.+2ERYS)#N.Q
M66U&7[Y,.6U^<S&S2?4CCQ74GT_:/5NU_0SU*[IR5^3T[)L]G,\<N[B<%8CV
MQ2T?.O'TTQVCZ7F7<GK/Z>=M8[?-W^/=[N(X8MK,9[3/L\U9^56?HODK+99I
MCAIK?6)QKG(D-Y_E[1H=1/MX:$T=6\G\1'4T3BY#!O-KZ=)$E3SI*02VR9,S
M2-Q?3O[O7:'9GDZAU>(ZKU^NDQ?+2/DXYY_S6&9M76)Y9,DWMK$6I\OC#4[O
MWUW[J[N\^QZ7,],Z).L33%:?FY(_I,T16=)CG3'%*Z3-;>?A+,(>_O#0
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M]T
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MG]!&DP.VP
M                                    0[?;?[N>9?$GG5M3CQH.[UU7
MX+KFEUNTXUD6!0LCLEWV5:]QS.+)Q=G*?CJ4T3>3LH2VGN2CL,NO=W)396L3
M&LH:UO\ 61?9O_\ A3IW^U)4?_;QEY*A_K(OLW__  IT[_:DJ/\ [>'DJ-]?
MHB]E7,'V"["Y"1>05QA-EANJ<,PB16-XIA$/&'F\FS6\NVX:YDR*N0;[7Y5B
MLPDM&M'4^JNBNWJG"T1')*2@,
M
M    &K7GAZA>(G/.)8W^88K_  TW4]&6FOW?KB)"J\I>E)2CX_ZVJO&BEV'
M2;+;:RL6_P P;C)-J+-B]W<5&7;X\O&>%O:]A].?6_O?TXO3;;'-]KZ!$^]M
M,\S;'$>/RK?'@GC,QY)\DVXWQWY(3'/+U <N^!LFTR+*\7_B?I&-)44'>&N(
M<VRQF+#<>)N&>=TYH<NM=3W"=:0Y\]*JQ4IPF8TZ4KZGUV7;Y,7&>-?:^@'I
MQZX=D>H]*;799OL?<$QQVF>8KDF=./R;?!GCG,>2?F>6/-?'2&J\4/8@
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MD8Q']@
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M=V;M:S)Y4A$[8V=Y/FDEEY7D(UQW,CM+%4?HEY1$2.TDI49$1%]!EH.K
M 'FCR)$.0Q+B/O1945YJ1&DQW5L2(\AA:767V'FE)<9>9<22DJ29*2HB,CZ@
M-BF@O;;[$N-SD1K7O*;95I0Q/"VC$-F63>VL41":42CK8%3L9G)/T_#=Z'W?
ME:X+A=QFE:5&9B)K$B1/Q(^Z.Q2[D5.+\T]*KPM]];<:5MC21S[K&&5N.$@I
MEUK._FS,GJX$=O\ &^[7VMQ(6?\ 2H?]",)I[#5*#T?R#TCR5PB'L;0VT,.V
MIADSQH_.<1N(]C\"2XV3OY;>5W5NUQVY:;,C<A3V(TMK^C;28KTTYI=Q
M
M                    JYO;-FA9[[*.:EX3BG/@[]S?"^Y7=U(];S$Z[-O\
M4:(?:T>+=I?@,NA?1;A='%7U^&$->0D $VG[4W!_@:/Y;[)\/;^K-K:]P?S]
MO],_A[B-O?>'N_E\'\3N[I_)Y/\ ;%>0A*]%:0
M
M                 '@E18LZ+)@SHS$R%,8>BRXDIEN1%E19#:F9$:3'>2MI
M]A]I9I6A1&E23,C(R,&5+WQWC)CF:Y*S$Q,3I,3'&)B8XQ,3RE'7Y^_;P<=>
M0Z;O8?%EZJXU[?D_(G.XO$ANJT=EU@ZXX\M$O&8#3LO74E]2B0E^C0=>RA/U
MK'%J-TN)EVE+\:>[;]QM%Z:_>?[H[7G'TOO&+]6Z'&D?,F8^UXJ\N&2=(SQ'
M/3-/GF?^M$1HAG<IN&G)'ACG*\"Y#ZQO<'GO./E0WZFOS'"LPBL&DU3\/S""
M3U'?QTMK0IQMIWY,7O)$AIESJ@NNOCOCG2\:-\.SN_.U>_>G1U+MC=X]QCB(
M\]/ARXIG\7+BG2])YZ3,>6VFM;6CBQ>&#]>            R3XR<0^1?,/.F
M]?<>-7Y#L&Y0N,=S8PV$PL5Q.%)=)I-IE^5V"HU#CD OJ:3DOH<?-)H90ZYT
M0>=,=\DZ4C67Y3N[O?M;L;IT]3[HWF+:X)U\M9G7)DF(U\N+'76]Y_BQ,1SM
M,1Q3*> ?VZF@M!JI-B\M9]1R/VM$4U-8P=N)(1HK%IJ#ZI;<I[-B/9[.D,F7
M7RV[,:M62S2JL4I"7C[#%M*4XY.-OW/^+1+U*^]'W+W)&3I?95;]*Z-;A.;6
M/M>2/XU9FNWB?9BFV2--8S:3-4CJ! @U<&'65D.)75M=$CP*^O@1V8D&!!B,
MHCQ(<.)'0VQ%B16&TH;;0E*$(21$1$1$.8U7R9,F;);-FM:V6UIFUIF9F9F=
M9F9GC,S/&9GC,O;!@  #X^0Y%C^)4EIDV57M/C..4D-ZQNL@R&SA4M)45\=/
M?(G6EK9/QH%?#83]5NNN(0DOJ9D)B)F=(YJL^?!ML-MQN;UQX*1K:UIBM:Q'
M.9F=(B/IF48'G_\ <FZJUD5YK7@[20=RYRT4NNE;GR>+.B:FQV6E3D9Q[$Z9
M1P+S8TZ*XA2FY"S@4W7Q.M.V#*E-CGX=A:WO9N$>SQ_X-?N]/7CIW3_/L.T:
M1NMYQB<]XF,-9Y>Y7A;+,>WW:<IB;QP0[]_\DMZ\I<_F[/Y ;.RG:&9S$K9;
MLLCG$N'3P5.K?*HQFBB-Q:'%:)M]Q2T0:V-%B(6I2B;)2E&?:4QTQU\M(B(:
MO]:Z]UCN+>SU#K6XR;C=SXVGA6/R:5C2M*_FUB*_0Z0&;J0        !V-JG
M;VT=%YQ3[*T[GV5ZUSRA6I57E.'7,VDMH[;O:4F&Y(ANME,K9S:>R3%>)R-)
M:,T.H6@S2>-JUO'EM$3#G=-ZGU#H^[KO^EYLFWWE.5Z6FMH]L:QSB?&)UB8X
M3$PEO< ?N7JNP32ZU]@&/%4S^K$&/R*UY1K<J9/4D(^7LG6U-'7*K'2-*EO3
M\=:?9<4M*$U3"$*=/K<VP_&P_M3^]/\ #^VV5[+]>\=_)L.]*>6_"(W.*ONS
M].7%6-8^FV*)CP^76(U2O]?[$P+:^(4FP-8YEC.?X/DD0IM#EF(75?D%!:QC
M4:%.0K2L?DQ'E-.I-#B25WM.)4A9)4DR+K;5M6?+:)B6Q^RWVSZEM:;WI^7'
MFVF2-:WI:+5F/HF-8^OV3PES(0Y0                         Q.Y<<W>
M-/!_ 5; Y$;(J\2CRFI/Z9Q.*I%KG^<S(J2-==AF(1G2M+AQ+CC:'9!DU AF
MZA4J0PA1+$Q$SR$*OGK]Q-REY)KO\"XVIG<7=-S%/046=#9>7>&3UQ.&E+]M
MGD%3:,'3-0VASXF/DS)C&I;*[*6T9F=D4B.?-"/58V-A;SYEK;3IEI9V,EZ;
M86-C*?FSYTR2XIV1+F3)*W9$J2^ZHU+<6I2UJ,S,S,9CTP            &Z
M/UN>[/DOP,F4F!9%+G;QXUM2(T:7JS*;5Y5SA=87:TZ_J?*)?R7\:5%:(EIJ
M7R>IGC2I*68SKJI2<;5B?K$_3BORQT7S-U)3;HT!FD3+<2LU%#LH:R1#R7#\
M@;89D3L3S2A-UV3C^1UR)"#6RLU-O-+0_'<>C.M/.53$QPE+(\0
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M*V:^_"EO$11I9.O-PD5VIIQCDE(\&
M                                                   *B7=6:%LC
M<FVMB$[YRSW9N>9H3W:A'F+*<IM;PG>QMB*VGR%.Z]$M-D77Z)27T*^.2'68
MD %A/]M7A'Z4]:<"^\7C_B9O7:V;]W^[? 1C6M_+_37/V?P^[/V-_P S^;_1
M*IO\26_\8@
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M91$:6M#5C!1,:<:>;-4>;$=:D,J4TXDQ3,:3HEEH(
M                                      !73?<6YO\ JSVB[2I"<\B=
M:Z\T]A"2_H6_F8)6["6VD_$V1]KN>*,_Q.=%&9=Q&78FZGPH:,AD "55]JG@
MWYAR)Y4;+\'=^DM+8G@WR>SKX?XAYRB_\'E\*NSY'\+^[M\B>[Q=>U7;U1A?
MD0F^"I(  *G7FEI>_P"._+3D3I?)8TF/88#MS-:J*Y+9<8<M,>DW,FUQ+(6F
MW4H7\/)L4L(5C'49%WQY2%?RB^.2&,8D  !,S^U4T;=P,:Y4<C[2$XQ19):8
M1IW#9BS<04Z7C#-GEV>&EHUI0['C?J&A0V[V*+R>9"5$:'$BN\^!"7F*T@
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MU0X9,S'%5YH>KZ[5\8$TQ*DK2E:%)4A224E23)25)475*DJ+J1I,C^ABM+]
M
M                 '1O)[-2UMQJY#;%-[XQ8#HW;6:G(_!^X+%L!O[TWOWB
M5M_NB@=WXB,OI]2,A,<Q4EB]   +.CTOX6>!>KSAS1FV39SM:3LT[4]O0RV1
MFF4[$)S\,J675TLI[C_&1]3^J&SZMHHM\4I;/A
M
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MW_:/>W0N]-C]KZ1D_GJQ'S,5M(R8YG\JNLZQ/A:LS6?;K$Q&<(I?K@
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M+API;7R:[S'(2PA6D
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ME<0^U41@GZ[U\8$LL5I
M                                    &LWW)9L>O_6'S)O2>2P<_5"\
M)[U.);)1;+R7']<&SW*-)&J265^,D_M6:NTNIGT&5?B@5A8N0  "VHXH86>N
M.+7&O7BFO K M Z<PM3/<M7A/%]=XY1FUW./RG%>,X/3JIUPSZ?52C^IT3S2
M[^$
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MA5>3)3%7S7G2'=]![;ZWW-O(V'0]ODSY_'2-*TCVWO.E:1]-IC6>$:SP3*N
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MT2- KX$9B%!@PF&HL.%#BM(8C1(D9A#;$:-&8;2AMM"22A)$1$1$*DO9
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MNYQ^/*R:8^W#[UN*8KVH[!*-#211,ZSJEF&(                 !TKR)Y
MZPXM:8S[?.XK]O'< UY2N6UM*Z)<FSY+CC<.HQ^DB*6V=CD&1V\AB#!CD9&]
M*?0DS2GJHIB-9T%9=["N>^V?87O^WW%L5UVGQFN*50ZHUK&F*E4FML&^8Y)B
MU,=Q+,5NSR"Q4:7[:T6TAZ?*(B)+49F+&8NB-(T0P4$@ ^I24=UDUS58YC=1
M:9!D-]8PZ>CHJ2OEVUS<VUC(;B5]755<!F1-L;&?+=0TRPRA;KKBB2E)F9$
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MG6'>E%HTG1+8@(
M                              &@[[DG-SQ/UEY%0E()DMF[GU+A!MF\
MEHY90+"UV1\=*%/LG(-)Z^)WL)+ID31J[2))K1E3XA7E"Y  ["U)AB]C;6UE
MKUIM3SN=["PO#&V4FXE3J\HR2MI$-I-I2'24M4[H1I,E?7Z&1@+>-*4H2E"$
MI2A*22E*2)*4I271*4I+H1)(B^A#CI?H
M
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MN9C0:^#%:226VF6T-H270B(A ^N
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ME!%C>-8%B4*4@
M                            (J'W5V<*K^/O%/6I/FE&6;DS+.%1O(9)
M=5KW"6Z%+YL_+02SCELXTDKP.=GE,O(WW=KN=.:)0B!: #8!ZJ<)+8/L?X6X
M\IE4A$;D'K[+GF2;4ZEQC7MNWG\@G6TI5W1R8QE1N]Q=GC)7=^'J(MRD6DPH
M2
M
M Z=Y#;7A:(T)NK==B3*XFI=59_L9QA]1)1,7AN*VE^Q 21J0;CU@_ 2PVVD^
M]QQQ*$]5&1#*E?/>*>V8AU?6^I4Z/T;=]6R:>7;;;)E^OR4FVG[,QI'MF=%3
M'?WUQE-]=Y/D-A(MK_([>ROKRUEJ2J59W%O,>L+.PDJ2E*52)DV0MQ9D1$:E
M']!^DB(B-(Y/FWFS9=QFON,]IMFR6FUIGG-K3K,S],S.KY E6 -EOK+]9^UO
M9%MV?BF,V'Z&U/@J(%AMK;$NO.SC8S$LCE?E%#159R82;W,<B5!>*+&-YIEE
MEEV0\LDMI;=X^XW%<%=9XVGE#][V!V#U'OOJ=MMM[?)Z;ATG-FF-8I$Z^6M8
MUCS7MI.D:Q$1$VF>&DV 7"_US<3^!N,E4:%UQ%C95-@E"R;;&5''R+:F7(,V
M%/-VV5NQ8YUU6^[&;<.LJV:^I2Z@G$QB=-2U=-ESY,TZWGA[/!NAVKV-VWV=
MM_E=&P1&XF-+YKZ6S7^N^D:1PCW*16FO'RZ\6<PI?KP              8K<
MK.%/&?FKA)X/R*U;19Q&C-/)Q_)20JISK#Y#IDLY>(YG6G'OZ0U/(0MUA#QP
MY?829++S?5!V8\N3%.M)T?G>X^T^@=U[3[)US;TS5CX;<LE)]M+QI:OTQKY;
M?C1,<$";VS>HO.O7!E--EF-WUCLOC9G]O(J,+SNPBLL9+B]^B,Y/;P?8C5?'
MCU173T!EYV#/BH9C6C49Y9,1EMK83W.VW,9XTGADC_YP:;>I/IGO.Q=Q3<X+
MVW'0<UIKCR3'O4MIK\O+I$1YM-9K:-(O$3.E9B8:;!RGEP  +2SUF;XE<EN!
M7%O<5G/=M+^^U74466V4AUQZ38YIK^1,UYF=C)<>6MY4BRR?%9<A1J49F;O7
MJ?7J?Y[<4^7FM7PU_#Q?0WL'K%NO]F].ZIDF;9K[>M;S/.<F.9Q7F?IF])G]
MEG2*7Z\           !_#CC;+;CSSB&FFD*<==<4E#;;:$FI;CBU&24(0DC,
MS,R(B(!6F>YKV R>>O+G(+3%;9<K0FG5V6NM(Q&'GCK[>KB32+)-D^)PFR.9
ML6WB%(:6;33B*AB PXGR,+6NZL:1]*&H\9  Y9@>"9AM#-<4USK_ !^QRO.,
MYR"IQ7$\:J6B>L;S(+R:S7U=;$0M3;9.RI;Z4]RU(;01FI:DI(S(++KU5>MO
M!_7-Q^BXF@JW(=Y9^S5WV\]AQ6NXK?(([#RH&(X_(>;1+1A&$IFO1X*5DA4I
M]R1-6VTN2;+5-IUGZ$MH Q
M                                      &K_P!T6;?H#U=\Q;WO\?S]
M:U^$]W;W]?XEYMBFN>SI\2;T\OZJ[>O87;UZ^1KIY495^*!6,BY   +;'B[A
M'\,^,W'76_B\/\/M%:CPCP_[E^E, Q^A\7]-?_I?P.G\]?[/YQ_M''GFEWJ
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MM=?O+D[#N<6@RZ^2EJSPK4[#3</8&6-N-+.57V5VU.12U;I);7WRI<F.ZEZ
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M&G7\4V)$9C]REQXC6:4DXXR5=#5%4VO]BB,Z)C2=$LQ!
M                                                           "
M$?\ =89S^8;YXFZT\_=^DM19WG/QO)U\/\0\R@T'G\7F5V?(_AAV]WC3W>+I
MW*[>B+,?BB44D6  W?\ V[V$%EWM*T[;KCJD,ZYPG<&;O)-E3S+1NZZO,(BR
M'R)AYMM+$_-&5-K6;9)?)LTJ[^U*L;_"+&<4I
M
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M#:7H\F-(94MI^.^TLE(6DS2I)D9&9&,1[       XIFV>8/K3&[#,MC9GBF
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MV_G+Z5-^-USQ;"NL%BONI-EI9^>OPAE3:C-?<R:#)7::4IIO\26\$8@
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M,&AQC%J6JQS'**L81%K:6AHX+%945-?%;(FXT&NKXK;+3:?HAM!$7T(4)?:
M                :,/N%.+C/(3U[9EG556E+SOC/;P]RT+[+*%358E%3^2;
M0K3D*_$S5MXA/7<R$E_3':-C_8&5)TD5U N0  ";G]K#OQW(M'<C.-UI--R1
MK'/\>V?BS$AWN<_3^S:J12WD*O;Z=40:>_P5$ETOV$_<=?VJ,5WYZD)68K2
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MM9R<&SR6MPR0;<+!\\AXUE-BIIQ1)6J-$>0E2D_BZ*29XS68YC.(0
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M4\;YUI0X%L+&<COH%?WMM_F4FDKK%ZU:K/*ZE'R39\'D/L[N[Z!I,<QD4(
M          &-^Y>8G%/CQ<0<>WGR+TSJC(K*,4Z#CV=;#QC'K^1 5]$ST4D^
MQ:M"@+471+YM$TI7T)1G]!.DSR'3/^=+]<?^.UQK_MKXI_R@&D^R0_SI?KC_
M ,=KC7_;7Q3_ )0#2?9(R4TMR$T?R-Q^TRS0^U,(VYC%+<+QZVR# ;^#DE/
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M_P!&9PU_[GJW^NUN/S^Z_M%_K?0'TQ_T#TK^ZQ^&S9(*'[L
M    8V\R_P#! Y6?Y-N\_P"YAE SQ?I:_P :/PNA[I_TQU+^X;C^JNJ?!^D?
M.$  $_[[9K_1SWG^4ELW_HKK<=+O_P!/_P L?OMS_0+_ $-?^_Y?Y&)(7'">
MV@           *U;WB<N7.6GL!VG)J+#Y>N='O+T3KM#2S5%>BX-8SVLPO6C
M(DLR?U!GTFS>9D)3^]KTQ4]RB;2H[JQI"&H(9  R6X=<:,KYA<FM.\<,.6N-
M9[.RZ+56%LELG4XYBE>Q(N\UREQI1DEY&-8C639WC,R-Y3!-E^)9")G2-1:L
MZTUUB&H==X/JO *AFAPC76*4.%XI3L?5%?08W61JFLCJ7T)3[R8D5)N.JZK=
M<-2U&:E&8H2YN                             PTY<>P'B9P?QX[KD/M
MV@Q:WDPUS*'7U8L\BV;E*"[T,G0X-4G(NG(;\A'B^?(1&K&'#(GY+1?43%9G
MD(FO+O[GKD#GS]KC7#W6]'HG%E+>8@[$SZ-5[!VK,8(UDQ81:"2U)UQB+SB%
MEY(CS&1]JD$I$KH9I*R*1XHU1V]U<D^0'(Z\/(]\;EV1MJU*0[)BN9UEUS?P
MZM;O=WMT53-EKJ:"(1+,DL0F([*$F9)01?09Z1'(=)        S7XT>Q;FKQ
M$EURM$\A=@XQC]<MOMP"UM3R_6C["5)\L9S7V6(N<4C_ "62-M3\:*Q+;0?5
MIYM1)443$3S%ACZHN6NU>;O"G7G(?<>.XCCN991>9O2N-X/%M:_'[:!AV3S\
M7:NV*ZXM+J7 DS9=6^E]HI3K7E;4IOL2HFT4VC2=$MCP@  !6L^^;-BS;VI\
MGW6)'GK\8DZTPF 7<A7QSQG4F#0[F/W-N.(_#DISCZ?0T]W11$HC(75^%#3^
M,ARS \[S+5^9XQL37F2V^'9QAEU R+%LHH9CD"WH[JL?1)A3X,IHR4AUEU!=
M2/JA:3-*B4DS(PMD.-FSIN[..F@MS641J!8[<TKJS9T^"RTMAF%-SW!:+*I4
M1IAQQYQEJ,_:J0E*EJ-))Z&9G]1QYYI=U ,?.3G*32'#[4M]NG?N;0<,PND(
MF(Y+(Y=[DUV\VZNOQ?$:-D_G9!D=H;2B:CLET0VE;SRVH[3KS<Q$SR$#[V&>
M^_E1R^L[S"=,6UYQIX^N+E08N-X?;N0]EYK5K)+'R=AY[6+9G1T3VDN&NHIW
M(M>AF0J/)78]B9"K(I$<^:&AY2E+4I:U&I:C-2E*,U*4I1]5*4H^IF9F?U,9
MC\  %L-PEU7_  0X>\8-2N1F8L[ =#ZMQZ[;CH[&G<EBX;4*RF;V]",EV&1.
M2I"_Y36X9BB>,I90"   'S;FZI\<J+3(,AMJVAH:2!+M;J[N9\6KJ*BKKV')
M4^RM+*<ZQ#@0(49I3CSSJT-MMI-2C(B,P$5WV&_<I8+K>;=ZKX(4E-M;+(3T
MFMM=[Y=&EKU?5/MI-A_^'^.LO0+//I+#ZE>.RDN0Z@ELI6RW9QG266<4]J$0
M[D-RJY%<K\O<SCD/M[--IWWFDO0$Y':K.BH$RS;.1%Q3%8*8>+XE7NFTGNCU
ML.*R9IZFDS^HLB(CD,?A(    RXXH\Z^57"C*"R7CKM[)<*CR)*)-[ACLC\[
MUSE?3Q(6638';_+QNRDKCM>)$WP(L8S:E?'D,J/N$3$3S$YKU<^\32O/1=7J
M39L*JTARA5&4;&'O6)_H39ZV",Y#^J[FTDJG*N4M)-]W'YJEV#3/5<9Z>VS(
M=9JM73ZDL"_NM,T.#IWB!KOR$193LO9^:&U^'N6>!8MC-&3A=8JU]&RV09'T
M>;+\9=4.?13<TYHE"A%H -B'J6PL\]]E7"RC)LG#@[ZPW-.U7;T(M;R'=B&Y
M^*5$+JT6+=Q?C,^I?1#A]&UXV^&1:+"E(  .';%RUC =?9UG<HD*C85AV3Y;
M(2YT\:F,<I)UPZ3G5U@NPVX9]?QH^G]$7[0%0C+E29TJ3-F/NR9<R0]*E27E
MFX](DR'%//ONN*,U+===6:E&?U,S'(0\   LH?0IA!81ZK>,J78YL6&6-[,S
M>Q-3*F3?/(ML9N[3R.UQAAU9+QEB"1+5WDLD]4*-LT"FWQ);A1B "%![YO9%
MS T%SSE:FX^<A<YU=AN*Z>UT=KC>)3ZIJ"[E%ZYD&1S+28TN#*D(L951;P6S
M\JB6;+31D78:3.RD1,<4-+W^>$]FW^.9N/\ ^)U7_) S\M?8'^>$]FW^.9N/
M_P")U7_) >6OL&NNYN+/(KBVR"[FO65S>64ZXM[&09*D3[.SE.S9\U\TDE)O
M2I3ZUJ,B(NY1B1\T  9TZO\ 9GSTTK@6-:NU3R?V5@FOL/ANU^,XGC\JJBU%
M-$?F2;&0U$9.K<47R)\QUYQ2E*4MUQ2E&9F9B/+ Y[_GA/9M_CF;C_\ B=5_
MR0'EK[ _SPGLV_QS-Q__ !.J_P"2 \M?8'^>$]FW^.9N/_XG5?\ ) >6OL&;
MWK9]C_L6Y \\N*FH\MY8[:R7$,KW'BSF88[-LZTX-]B../N95E%//2W4>1<"
MRH:.0R^E)I-32U$2D]>XL;1$0-X7W'7-/D)Q,Q7B?4\>-LY/J>^V1D&W['(K
M'%'&6)UI48/7:\C1(4IZ0U)91$1,S0UDDV^Y:TD:5$2%$K&D1/-**_\ YX3V
M;?XYFX__ (G5?\D"SRU]B#_/">S;_',W'_\ $ZK_ )(#RU]@PFW#N7:/(#85
M[M?<V;WFQ-BY,BJ;O<MR)]N1:V3='3P,?J6WULM,,DB#35<=A!)0DNQLNO4S
M,SGER'60  ROT#SFY<<6<;N<0X][YSO5&,Y#>'DEU38K+A1X=C>G AU9V<A,
MF%*6J2=? 9:ZD9%V-E]!$Q$\QWO_ )X3V;?XYFX__B=5_P D!Y:^P/\ /">S
M;_',W'_\3JO^2 \M?8'^>$]FW^.9N/\ ^)U7_) >6OL'E9]OWL\DO-1X_,?<
M[\A]UMEAAF?6.O//.J)#3332*=2W'7%J(DI(C,S/H0>6OL%FQAU=<5&(XK4Y
M%9NW>05>.4==>W+RDK>M[B%618UG9NJ2VTE3L^:TMU1DE)&:_P!A?L%"7(P
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M_OMFO]'/>?Y26S?^BNMQTN__ $__ "Q^^W/] O\ 0U_[_E_D8DA<<)[:
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M(U)C.*4=3C6.TT)*DPZBBHH$>KJ*R(E:EK3&@5\5MILC,S)""ZF8H2^X
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MKO*<FG*F3Y'87;'B1FTI;AU=3 9Z-1845IB'$92EIEIMM*4E;$:<D.L@
M     !MS]4OM<VGZ[-H0*JSG7.9<7\QO&E[4U6EPI2ZPYOQ(DK8>O694AABL
MSBJBQFS<9\C46XC-?&DFE91I47&U?-]8L>=8[,P3<VO<.VKK#)JW,=?Y]05^
M38GDM0Z;L&UJ+)DGF'4I6EN1%DLF9M2([R&Y$60A;+R$.H6A-*7.@   >M-F
MPZV'+L;&7&@5\",_-G3IK[46'"AQ6EOR9<N2^MMB-&C,-J6XXM1)0DC,S(B
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MAUGH_L;D=L+(&9"D]%.5=+BNO\,C,)/Z$IEBRQR:HOY>]U?U_8157YIA(J&
M     -3/M#]M&E_7#A2*N0W$V/R+RVH>FZ[T[#G&QX8BW'(C.:;"L(R'G<;P
MR/+;632.A3;=YE;$1))1)E1<JU\PKVN5W,'D%S5VA/VSR$SZQS&_=5(8H:=*
MG(6'X-3/NI<1CF"XRAYR!CE*UXT=R6R5(E.)\\IU^0IQY=L1$<D,9!(
M    .R-1;>V7H;8N*[9U!F5U@6PL+M(]OCN34,GX\R))861K8D-+2Y$LJN<U
MU9EPI+;T29'6ME]MQI:D&F-8TD6,OJ4]JV"^Q_5DF!<L5>%<E=;U<%6UM=QI
M!(@V\):VH+>R<!9DONSI6&6DYQ#<EA9N/TLYY$9];B'8<F73:LQ]26WD8@
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M.Z-3FA.T]0[0UHIQ9MMIV!@&5X::W"6;9MH+(JFM-2R<2:>A?7J703J.KP
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M9:ZVT\$) OVU7^C3@_\ ?MM;_P!#&1C?XDM_XP
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MN@QI\27G^VJ_T:<'_OVVM_Z&,A?XAO\ Q@
M      -57NZ_T67+S^P_#?[JV!#D;3^T5^O]YYUZM?[=]3_54_KL:L_'?M"
M  6>/I__ -&9PU_[GJW^NUN/S^Z_M%_K?0'TQ_T#TK^ZQ^&S9(*'[L
M           8V\R_\$#E9_DV[S_N890,\7Z6O\:/PNA[I_TQU+^X;C^JNJ?!
M^D?.$  $_P"^V:_T<]Y_E);-_P"BNMQTN_\ T_\ RQ^^W/\ 0+_0U_[_ )?Y
M&)(7'">V@          KXON5=MNY_P"QR3@#;RO@Z+TWKC"%1"5U;1<93%G;
M6G333VD:9$JKSVO:5]3(T1D?[8MI\*)1]AF #*3A#IQKD%S!XS:8EQU2:G8>
M[==8_DC:4>12<1=R:OD9@^EOZ$X<7%H\QTDF:25V=#,B^I1/(6P0H2
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MB+NXC[T=;$R!KJE<7.AZZHG$/.H,HKCME*:<-$N9(03:&ZIM,_4EM@&(
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M=2W^/VEA27E-9QG85E4W%5+=@6=980WTH?B3H$UA;3K2R);;B#29$9"Y#Y8
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M%MC6B67&VY4%V9$63E=>;5:4HEOR5$]%IG4DW#-3[:I:ZK6UX1R$ET8)
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M<E7NB\B1W$CYR-CUJXN(PNY7T_'LN!1.=/VJ\?:7U,C&-_A%E,*4@
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M)A-/B#[:K_1IP?\ OVVM_P"AC(7^(;_Q@
M     -57NZ_T67+S^P_#?[JV!#D;3^T5^O\ >>=>K7^W?4_U5/Z[&K/QW[0@
M  %GCZ?_ /1F<-?^YZM_KM;C\_NO[1?ZWT!],?\ 0/2O[K'X;-D@H?NP
M            !C;S+_P0.5G^3;O/^YAE SQ?I:_QH_"Z'NG_ $QU+^X;C^JN
MJ?!^D?.$  $_[[9K_1SWG^4ELW_HKK<=+O\ ]/\ \L?OMS_0+_0U_P"_Y?Y&
M)(7'">V@          JS_:3L!>S?8MS/RI3R)+2.0FQL4@R&C)34BJU[>2-?
M4\AE:7GTN,O5>,,J0HE=%),C[4]>TKZ\H0P)$@ WB_;MZ\;SGVAZIN7VDO,:
MMP/;.PW&E^ VS<5A<_ H+JT/+2I:HMEG;+S?C)2TNMI5T)*5*+&_PBQA%*0
M                       !!'^X0]I4G?\ LBTX4:2R!TM(:CR/Q;;O:J4:
M(NU=K4,CM<HC=87UGX3K.S:4TVVKHQ-OFG)/8XB'7R!;2NG&>:$9$9@ S:X"
M\$]N^P3?M)I35[/Y55M(3=[)V-/@R)>.:TPIATD3+ZU2RIDYME,<_J:KKTN-
MN6$YQ"#6RPE^0Q$SI&HLJN('$#2?"'2>.Z-T;CI5./U)%.OKZ<3#^59[E3[#
M+5KF696K3+!V=[9FPDOHE$>)'0W&C-LQF6FD4S.O&4LHA      (L_W4^;?
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M)S_*-083'6E2T.K)6SL9RR=':4AQ'_UFIQ20VX1DHE,J673Z]2RI\0KBQ<@
M<QUWB3^?; P7!8IK3)S3,<9Q*.IOKY$OY'=0J=DV^C3Y]Y.3"Z?@7]?Z$_V
M+>V)%C08L:%#8:C0X<=F+%C,H)MF/&CMI988:;21)0TTT@DI(OH1$..E[
M             (V_W06P/TYP.UM@T9Y")FQ^1V)LRF%&P:GL>Q/"L]OIRVT*
M>3)[V;[\J_$AM2"2HR6I)J02\Z<R4"$6H  !9[^G+7J=9>L;AOCJ8ZHYVNI(
MNPEI4EY*G%;8O+K:/R#^0RPXI,A.8$M)]#1V&78I:.U1T6^*4MEX@
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M7:.PTQV4I(U+==2E)&9D0F.,Z"I=SG-,CV1FV8[$S&Q=N,NSW*<@S3*;9_\
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MMKDR,=_4V8Y;VW=V44K2;^;YSD.37I_**&W^[.5X4=OX$)ZGU3,SQD9 "
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M^^)K_C7B#,F/Y.[P7V3YWL6[FJ[$O+0WYJ,ZP^AH0X?;U/N3V=+:<D2C;C,
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M.85T-$BNP_+*[,+*,X1_M;D0*)Q"NG0^U1]/J(MRD6GPH2
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MXIB5'58UC-!5,)BUE)0T<%BMJ*JOC(_ Q#KX$9MIM!?S4((A0E]\
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MQ_781#(E))1Q]HY]5*>1^(NY*<=BRF3_ &E;QU?RD*[SX$)B0K2
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M_P ?S]:U^$]W;W]?XEYMBFN>SI\2;T\OZJ[>O87;UZ^1KIY495^*!6,BY
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M]"6IU7CE'73&TK0ZEN7"K(L:0A+C9J;<2AYHR)23,C_:0XZ7(P
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M*8Y",TKDN1H#7]4V=E(0AOYMU=SW'ILZ29$N3,D.NJ_$LQ1/'BEVP
M"%1]UOER9NV.'6!D_P!R\;UWMC+E1N]D_"G-LEP^F0_XTI^0GY)Z_4GJHS0K
MQ?A(C)?6S'XHE$P%@ -I/I3P\\X]I'#RE)MEWX6P;S,.U]IAY!%KW7N99\;B
M42%);)YHL:[VUD?>VXE*D$:R21XV^$6;HI2  "M%]W?*)WE+[$MUVL"P3.PK
M3LXM!8#XE$N,FHUI/LH>1S(SJ22W*CW.PYMS-9>3U)R-(:(E*0E)G=6-(0U)
MC( $B#[;WB"QOKF?8[YRFM^;@O%2CB99#2^V2X<S;.6G8U&NV'4K;-+GY%$@
MVMRVI"R6Q.KHBC(TJ,CPO.D:"P&%20            !Q?.,RQ[76%Y?L'+IZ
M*K%,$Q>_S+)[1PNK=;CV,5,N[NI[A%TZHAUL%UP_]I("ILY(;OR7DIOS;^^\
MO-97^V=@9-FTJ(IXWT5,:YLGWZJ@BNJ(C.!CM1X($8C_ )L>.@OY!R(C2-$.
ME  !.&^U[XI,X9H?;'+S(*XDY#N?(W-:X!+>:0;C&M]?2R5D<V ^226F/DVP
M%N1I*#,R->.M']/Y:KSQT(2H!@D         0TONP<?BQ\BX.94VVGYMM2\A
M<?ENE';)7Q<>G:9L:]MR4E/E<3Y<GE&AM1]J/Q&DNJEBS'XHE$&%@ -@7JFO
MEXY[(N%%@B1&C*D<B-<T)N2W";:4C*;MG&'(Z%&XT1R9;=N;3*>IFIY:4D2N
MO:<6^&1:2"A(  (7GW7.<*EY_P --:MOJ2F@P_<.<2XR'#)+RLNNL$H:Y^0R
MF6HG%1BPB4EE2F$=GE=)+B^Y:6[,?BB41P6  W)>@?"3S/VI\;W7(_R(&'1M
MJYM8EVK5XBJ-29M$J)'<EMQ"/#DMG!/JOM(_V$?<:>N-_A%DH*4@  A&?='\
MHG\HW1I/B/16'=1:LQ=S;6=QF%F;3^>9Y\FIQ:!8-FX?29C&%UKLIDR0DO#D
M2NJE_0D64CQ1**8+  ;%_5!Q49YC<\=#ZBN8"+#!(61'L7:#+[:G(3^O==ME
MDMW43R0E2TQLNDQ(U&2B+\+EF@^J2ZJ*+3I M#DI2A*4(2E*$I)*4I(DI2E)
M=$I2DNA$DB+Z$*$OT        !B+[ ,<9R[@IS+QQ\FO^%>+6^V([CWD\4>>
MC5V4/ULM9,J2XI,.P::=[2/HKLZ&1D9D<QS%4F+T   LN_17?R,D]4G$6QDD
M\3D>@V90)\\I<Q?Q\4W?LS%XAI=<0A2&3BTZ/&UT[6&^UM)F2",Z;?$EMK&(
MC;_='2)#'K[U0TR^\RW,Y?Z]CRVVG5MHE1TZ<WY+2Q(0A1)?93*BM.DE75).
M-I5TZI(RSIS)0(1:@ ;_ /[:JF9L_99"FNO--+QW1.UKF,AQE#JY+S[F,X^I
MEAQ3B#C.ICWKCAK22S-#:D=.BS4G"_PD+"<5)      !'=^YBW3%U_Z^ZW5;
M4Y*+K?FX<,QTZQ+BT/2\5P)<C8]W8&A*T)=B5N1X_1M+)1*Z.RVC)/4NY.=(
MXDJ_L6H &^W[<+2DS9WLCQC/50S>H] ZWV%L:QD.M]T-%G>TKFL,?B+6?X/G
M+E9TY,CI_G?U M9?TLS+"\\!8<BI(     K*_=5H7^]\]E/)?'HD+X>/9]EC
M.Z<74ACXT617[:A,YA<E!9(B;1#K,SGVL!!(Z(+X9DDDD7:5U?A0U6C( $N_
M[5/>2HN6\J>-=A.4INYQ[#]W8I7J=,FX[V.V"\%SR4TT9FE;L]K)<=2HRZ&2
M8I=>I=.VN\>)"9N*T@   -:7MIYL1^"G"S9.TJJP9B[2RMG^&6E8RE(.0O8V
M6PYK46]:97W$ZSA%-&F73A*3XW%0$,*,C>3UFL:SH*PR1(D3)#\N6^]*E2GG
M9$F3(=6_(D2'UJ=>??>=4IQYYYQ1J4I1FI2C,S/J+T/" [XXQ<>L[Y7;]U7Q
MYULRA>7;2RN%CL.6^T\]!HZ[M=G9#E-JB.1OG38ICT.593.PC<^-%7VD:NA'
M$SI&HM6-%Z:PCCQIS6FCM;U_Y;A&K,.I,,QYA9-_)?B4T-N.Y9V3K2&TRKFY
MEDY,FOF1*D2WW'5?B69BF9UG5+M80
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M88@YG#.<;!C/M>6%)P/6\61G&1U4\NI=D;)HM&522OVD[/0(M.D:BT>%"0
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M67I+(D&[X6Y,?;%>_BN.I>=/JE#,/.Y51+5W%VF4;H9IZ]Q8VC6!9D"E(
M"O%^X/YP?WTO,N;J+#[?YNHN+'YOKJH^*_Y*^\V=(DQ_XJ9(GL/L=^':US%&
MRK\2.RH4\T?;)5UMI&D:H:$QF ":G]LAP5;QK!\SYY9[4K3>Y]^;ZPT8W,93
MVQ,'JK%IG8&;1"<;7U>R/**TJ:*\@VW66:J<G\34LC%=Y\"$M,5I
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M+"4PRXIY)FZ<?+G'#;2A9J0VI75)-GW87Y$)U@J2
M  ""#]T!R%5GO+S5W'NMF*=I>/\ K!%Q=1DNF26,_P!NOQ+VP9>82DDJ-G!J
M3'W6UJ4HR^4X1$DNIKMI'#5$HRXS !(;^VKXZ-;;YZS]O7%<J5CG&K6]WE\2
M0MORPT;!S?NP3$(DE!F3?E_(K*]GQU*)1MR*U"TEW))2<+SP%@6*D@
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M9-KV3G^XLV=Z="4XJ)L"WU\VXX7[2-4?!$=.O[4$DR^AD*;_ !);R1B
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M'L-C2DM>%=O-JX+:;K(93?51)GY+=KDV$GI]#D25F70OH*)G6=4N[Q
M   K/?>5FAYS[3^6=BEQ:XU+DN$X7%:4M:D1BPC5N#XM-;92LS\:';:JD/*(
MOIY'5&7[1=7X4-38R !*Y^U/PDY^]>6FQ_!W)Q74N X2<KM6?A/8&865ZECO
M)LVT_)+6AJZ&M)GXOH2B(S37DY$)MHK2 (^?W+&V58!ZY3P6-(<1+WANK76#
M2([*C2IVDQLKG:,Z0]^))*B,VN"0&U%]3-Q]'X3+N-.=(XBOE%J !]W%\<M,
MPR;'<2I&B?NLIO:C'*AA7?VO6EW81ZR TKQ-NN]')<I!'VI4KZ_0C/Z +=#6
M& TNJ=::\U=CB";Q[6V#8E@-"A+1,)12X=05^.U:$LI6XEDDP:YLB22E$G]G
M4QQTN<@             "'9]UKM5S_\ T_TA#E]&C_BCM7(H/XOQ.)_2^(X;
M+_FDDNQ*KY'\XS_%^POIULI[42AV"P &<'K3U0SNWGYQ%UO+91)K+?>N!VU]
M$<)1HF8UAMLUFV3PC["-2?F8_CLEKN_8DU]3^A"+3I M1A0D          $,
M'[KW)&Y6<<)L/);)NT6*;UR1:$LR$R$MY7;ZMJVUNR%'\1UE:L,43:$%Y$*2
MLU_1;8LQ^*)1%Q8 #8YZA\<?RKV8<,*R.3IN1=W8[D:O%X^_P8<Q.RZ29^52
M$^(HU&OOZ'W=G7M(U=".+?#(M"A0D  %9[[R<X_7OM.Y8V+;WEB462X7@\1L
ME=R(WZ%UCA6*V#*/J9EW7-5*<677Z..*_87T*ZOPH:FQD "8C]J'@Z35S5V3
M(82:TITA@]/)\1=Q)6>S+[(V#>7$ZDE1HJE$EI_Z]#-UOZ,J%>3P(3%16D 8
MM<X-JNZ/X<<HMM1928=I@6AMI7] \J1\7KE$?#K9O%6$2?VLNR\C=BM(4DC6
M2EEVDI70CF.8J?A>@  %DQZ$=3HU5ZO./BWHA1+G9CN=;8O#3XS*4O+,TNH^
M-2^J$I,S=P.HJ"/N-2B-/3KT(B*FWQ);CAB         #"_V-Y.G#^ '-6_\
M[L9^-Q:WI$KY#)1S<8MKC6V14U,Z29*T,J)NUL&3,C[C-)'VI6KHDYCG JJ1
M>@  %FGZ1\:+$_5CP_JR90Q\K",JR7L;=?>2H\SV?G.8&\:Y'[PER3O?(I)?
M@0I9I1^ DBFWQ2EM3&(UY^U[1<OD9Z[N5NL*N%^8W[NKYV;XQ"0A2I<[)=5V
M-=L^DK*\T=%HGW4_$40FOJE"SD]CADVI8FLZ2*N47H ':>CMMY+H3<NJ]VX<
M:/U1J;8.);"HVGEFB-+L,2O(5TS7S3)*^Z!9?#./(0:5)6PXI)D9&9&F-8T%
MKOH3=N \D=,ZVWKJ^U1<8)M#%*S*Z"42VE2([<YLTSJ>S;:6XF)>8_:-/P+"
M.9FN--C.M*Z*09"B8TG1+MP0    -,_N3]H6,>OW1%AC6%7-=8<IML4LZKU3
MC33L:5+PNNFID5T[;V205&X46HQU:7"JFWVU)M+AM#1-N1V)JV,JUUGZ!6]3
M9LRRF2[&QER9]A/DOS9TZ:^[*F39DIU;\F7+DOK6](DR'EJ6XXM1J6HS,S,S
M%R'K ,S_ %_<.LMYU\JM9<>L9.7!J[ZQ_.]BY/%8\Q87K"@=8DYEDRR41L%+
M;A.)B5Z'32U(M9D5A2D^7N*)G2-1:8X5AN,ZZP[%-?X741,?P_!\<I,1Q6B@
M(-$*FQW'*V-44M7%09J44>!70VVD=3,^U/U,S%"7)@     !J)]Y^@SW[ZT.
M0<2%"3,R+4M=5[XQQ1M)=5#7K"6=IETIM)F2TN*UI(O&2-)DHO+_ $1=4JRK
M.DBM/%R !]O&<BM\/R3'\MQ^6NOO\7NZG(J2>W_3(5O23X]G6RV_J7XXTV,A
M9?[:0%M]I79U1NO3NJ=Q8_V?DFU=<83L6I2A?D2U S3&ZW(HK!J_;WQVK$D*
M(_Q$I)D?0R,43&DZ)=FB  :TO;3S8C\%.%FR=I55@S%VEE;/\,M*QE*0<A>Q
MLMAS6HMZTRON)UG"*:-,NG"4GQN*@(849&\GK-8UG05ADB1(F2'Y<M]Z5*E/
M.R),F0ZM^1(D/K4Z\^^\ZI3CSSSBC4I2C-2E&9F?47H>$!DWPWXQ9CS'Y+ZC
MXZ84B0U8;%RJ) N+EF.<AO%<.@DNSS/+I:.GC./C>,PY,HD*-)/NMH92?>XD
MCB9TC46J.L-;89IS76$:IUW2QL=P;7>+TN'XK2Q$)2U I*& S7P6UJ2E)OR5
MM,$MYY75Q]Y2G%F:U*,Z$N=
M                 "$S]REZ_P"PPK9=3SQUO1K<P?9GY/A^]&:Z+U:QG9%?
M$;J\5S2:A@^V-59W10V8#[OC0TW;0$J==4_9MI/MMAFUK\FW..7U?\/_ )R:
MG>O/9=]IOZ]X["G_ &FX\M-QI'P98C2F2?9&2L169TTB]>,^;)"*@.Q:Z
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M;T=A]BXVVEYB!C->SG&>M1UJ3YU1+.;D= 2C(R;-V!T_$I!]M=Y\"$N<5I
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MW%,&L=6V3#AH-Z$]JS*+W!*]AWQ_@)+U#10Y#1=3/P/H[NBNI%3;XDMJ(Q
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M:[SX"4B*T@
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MC6M:QY:QI#7#>[[>]2W5][U#+DS[O).MKWM-K3/TS,S/#E'LCA'!PL9.*
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MF*$N3
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M;$B#D^@\OL?%T2P["D2=AZYA&^1F:U2T3\J<))].WPF9=>Y72RD^")0^A8
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M8AN*:+ M!;BS0W4]W<V6+:[R*\-Q/9&FK[D?!ZET9>/Z?1"OYIS',5*PO0
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MI*HP
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M..=:5B)7]8[X[MZ_AG;]6ZAN<VVGG3S>6D_QJ4BM9_9B6%XN?E0    !NNX
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M0US:6F64MP:B"Q7Q$)9CMM1VDICQTD24)2A/[$D1="''2^T
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M/J;0Q'9V.Z]KMQ^0Z\AQIB.TG*NYQQ7:3:"-7<CIW%%OAD6C@H2
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M6JD>.KQJCJ:"M;[6T=D"F@1ZZ&CL:2AI';'C)+HE))+^0B(<=+[@
M  PG]CN@O[Y[@SR>THQ#_,+G*M4W]CB,,D=ZI&>X43.=8 RG\231YLSQJ"@U
M%U,DJ/Z*_FG,3I(JL1>@ >_56EA1VE;=5$MZOMJ>?#M*R?&5V2(5A7R&Y<*6
MPOH?8]&DLI6D_P"122 63'//V/0N/OJYI^7../M5^P>0&I]<L:.AD:'%,[!W
M9@;.35-HV7XVG&L(Q]Z;=&2NK;WY:EDSZNIZTQ76=$JUZ1(D3)#\N6^]*E2G
MG9$F3(=6_(D2'UJ=>??>=4IQYYYQ1J4I1FI2C,S/J+D/" ST]:?#*[YW<O\
M5NBHT:=^BEV*<QW!=0C<;/'M38O)B2<LD_+;_%!G7A/,4U>[T42+.SC&HNSN
M,HF=(U%H]1TE/C-+3XWCU9!I*#'ZNOI*.FK(S4*MJ:>JB,P*RLKX;"4,1(,"
M%'0TTT@B0VV@DD1$0H2^H
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MR^27'O7"&U/+V!O#4^$I:21FIU65Y[0426TD7U-2SG]"_P#I">0MMAQT@
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M%Y'2V5SB&6UL>1*_)LHH)+GCDQS6M!D:'F5NQW67G*9B8G24L@1
M    T6^V_P!S^N. ^.S]4ZDD8_LKEG>033"QA;YS\;U'"FL+.-E6QSAK23MH
MHC2Y7T"76I4E)I?D&Q&-HY.5:Z\^0KU\\SO,MH9GD^Q-AY+;YCG&9W4_(LIR
MB^F.3[>\NK-]<F;/G2G3-2W7G5GT(NB$)(DI)*2(BN0XF  -DOJ[]>.<>Q/D
M?4:[KTSJ74F'.5N3[QSUAI1-XYA93.GY)525MKCGF>9G'=AU3:B7XU$[+6A;
M$5XA%ITCZ19HZ^P'#M5X/B6MM>X_78I@^"X_58MBF.5+!1Z^FHJ6&U!KX,9L
MNIFEJ.R7<M1J<<7U6LU*49G0ES    'XI24)4M:DI0E)J4I1DE*4I+JI2E'T
M(DD1?4P%0UMG-'-D;4V9L1Y2UO9[L#,\T=6X2B<6YE.1V5XM3A*_$2U*G&9]
M?KU'(0Z_  %@Q]L_AR\9];;]TII;9;$Y"[2S%M:R>)+Z(51A&OS=;-PS0I!+
MP92.K?1'<@^OXNX57YIA(.&         CC?<^9F>/^OS!,78=Z2,^Y+X)5R6
M.U?[RGH\'V5DTI[R>!QHO#;U<!/8:VUJ\G5/<E*R&=.9* D+4 #G&L,/?V'L
MK7F 14.NRLYSG$L/C-L$Z;SC^37]?2LH9)B/+?-U;DTB3V-.KZ_L0H_H:>0M
MZ6668S+4>.TU'CQVFV6&&6T-,LLM()#3332"2AMIM"2)*2(B(BZ$..EY0 !&
M[^YYU$O-.">![2A15.S]+[SQR78R2)Q28F(Y_27F)6?4D$:4&_ECE$DE*Z$7
M0R(^JB(\Z<R4!T6H 'TJ:XL\=N*G(*2:]6W-'90;BHL8YDF1 LZR4U-@36#4
M2DD]%E,(6DS(R[DD MF>+6^,?Y/\<]+<@<97&_+-L:[QK+W8D12UM4]W/@-(
MR;'%*<4M?R<8R5F77/%W+Z/15$2E%^(Z)C2=$N^Q         XOF.<87KRBD
MY3L#+\7P;&8:VFYF19C?U.,T41Q]78PW)M[J7"KV%O+^B"4X1J/Z$ ]?"-A8
M#LRE+(]<9QA^P,>.0Y$*^PC)J7*Z4Y3))4]&*TH9L^"<AI*TFI'D[DD9=2^H
M#F   B0_=6:5=L-><5>0\&.?9BV7YKIW(Y"$=QN(S6HB9EB).J(NYMJ&[@UP
M1&9]IJE$7T/IULQSX(E"W%@ ,A.)N['^-_)S0>^&4O.,ZGVS@V;6D6.75ZQQ
M^ER"#(R2I1T(U?\ "^/E)BGT_%T>/I]>@B8UC06R-/;U>05-7?4D^):TMW70
MK>HM(#Z),&RJ[*,U,KY\*2T:FY$29$>0XVM)FE:%$9?0Q0E]$       &('.
MKF+KS@KQIV#R#V"_&D.4$!=9@>)N2TQIVP=D6L>0C$<,K>G?(_X1G-&[->:;
M=5!JX\F6I"D1U$)B-9T%6UMG:6<;OV;GFW]E7<C(L\V1E-SF&57$@U=9=Q>3
M79LE,9DU*1#KHINDS%C-]&8L9MMEM*6T)25_)#KT  3Q?ML."[VD>/&1<N<^
MI?A[%Y)LQH& )F-)*;2Z+II2)4"6R9]K\7^).2LG8.-J(T/5];5OH,N]1"J\
MZSH),(P2  "-/]T9FQ4O!C4>%,2/%,SCDOC<E]GN1_5-%BFN]CS)R>SR)</Q
M75E6JZDE22Z=#Z&:>N=.:)0,1: #*?@SA2MC<TN)6"]BE,Y5R2TG33329D;5
M9,V/CB+63U2ZPLTQ*WRNF25I69(Z)/NZ")Y"U_%"0  =#\I-1EOWC5O[2))9
M.1MC3NQ]?U[D@T):BVV4XE;5%-.-;AI;;77VLIE]"E&1)6V1G^P3$Z3J*EJ;
M#EUTR77SXST.=!DOPYL20VIJ1%EQ75L2(S[2R);3S#R#2I)D1I41D8O0]8
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M.O32_P#)5"S.MKVZ/.Z=]_\ G.R:3,ZN?$<4?0U+9,^A=11,:3HEE2(
M      56/L>T&?&/G1R?TLS"374^+[8R&RQ*$AI++<? \V4SG> LH0@_'T9P
MW)8*#-/1)J2?1*?YI7UG6-4,)Q( -B_,3FU/Y#<<.!7'BNES/TSQ;T=-H,@C
MNH<CM3=DVN46M6MTDF2?GPZ;7.-T+,5Q?])>DS$MD2%FIR(C29D:Z!( +!+[
M=K@JYQHXF.<@<YJ41=L<JF:;+8B)+)E/QS3,)EU[752?E;[HSV5E.?OWS:5V
MOQ9L!#I$[&Z)JO.LZ)2%!@
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MK-5^ _CGBVI<ZLZA[M6I)J_^\3<)'TZFGO[NGT,8V^$65@I2
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MQ3,<UDNDTAMV4>=[/S?+X;TA:6&%/K;J[EAE"E$HR9:0DE*2DC.FWQ);7QB
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MTAB-$B1F$-L1HT9AM*&VT))*$D1$1$0I2]D
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MAR;U]CT-3DF0W$9[E;MHJJ*R:WG&HS?;E*&OQ&A"+,VS/\RD"REO"4(;@L
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M1C'&C1]3/+M[#<M8VML;*WD*;*1+2TN59F\XI"75H0:S))FDB%$\TLK!
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MI;U1@
M                                                 /$\RS)9=CR&
MFI$>0TXR^P\VAUEYEU!H=:=:62D.-.(49*29&1D?0P$+3W%^@^SPZ5E'*/@G
MB,NVPR0JQR+:/'BACG)M,.>6X4F;D6G*>''^19XDLEN.R<?;\DJK4DU0"=AJ
M3%@V5MX2A$J4E2%*0M)I6DS2I*B-*DJ2?125)/H9&1E]2%@_
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MXB;A:VG".8G.I2E"4H0E*4)224I21)2E*2Z)2E)="))$7T(5)5Z?W*&4(O\
MV7VU2EQ*SPC1^J,76DE/*-E<MN_S0FU$Z1(0HT9>2^C?5'11&?XS416T^%$M
M PS !8$_;+8+^EO71<9,Y&['ME\A]D92U*6SVNR*^GH,%P-AEM]4..MV'&GX
MA*-"2<?0AYQWHM*E+;15?XDPD.C   !7G_<G9L65^S&ZHB>4[_#/26I\)-!N
M*648Y\>\V/X4I4HR92HM@>3M+H1FX:NG51F=M/A0T$C, $J'[57"BG\E>4.Q
M?#W'BVC<>PHI'X/W19]GU?>FS]5$Y^_/6Q*^A&7[OZF1].N%^1"<**D@
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MI)UE+I#"ZYW\1I>*]G;,O+ILNV2E"513QV 9][*C5YB[%IZ+2NO)X$)EHK2
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MB<>Q_,<;D//MTV9X?:J;;;N,:NVV%&TZDDN,NH<CR$,R67F6[HF)Y(8Y"0
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M^WU^.H8VG2!9B)2E"4H0E*4)224I21)2E*2Z)2E)="))$7T(4I?H
M
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M9T_56RM783Y.[KW_ * Q?*+WL[/EK[?'_$OKU\#?7N_ICG3M:KOS(2R16D
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MLBKNE1?1XRR;>L,5R:"N9C>65:'%$DY5;+E1R5^$U]Q&161,3R'08D
M    !MGX?>E/GOS"<K;FCU7)U!K.:MEQ>T-W-6.#4DB"LV5JEXWCTB _FN7(
M>C.*5'?@URZYUQ!MKEM'U,L9M$"8#P*]#?#SAD]39SF-?_?)[QK%L36,^V33
M0T8GC-FTG\,G M9&_9T=0\P\E+K$RR>M[.,^@G(\F/\ S"KFTSRY);OAB
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MQ96"2,T&@BIM.L_0EN5&(
M
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M&V+ET9_8.Q&9A(\;LVNR_-'[NTQYV07\]NK5!C_7HEM)?083:92S[$
M      "/C[M/59R@]E&6<?9ND\XTABV+:>QW8,6PB;6R;8%)82+_ #JRQ5V3
M)J8^):XSJ"[#_+L1BI6MQR.[WIZ=JDDDRSK:*\QHU_U6SV _]L'#K^V!NO\
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M;G?AYYF<&:R9JCS<?B.5U?AN(3(JEJ\<FHJH4SM5T<><Z$983:92VH#$
M     $$G+_MD/8=F.69/E]CM_AT5AE617623R_B%NE72;>64FSE%W(X\,I5^
M_E*^I(21_P"P7[!;YX^E&CCO^JV>P'_M@X=?VP-U_P#A\#SQ])H?ZK9[ ?\
MM@X=?VP-U_\ A\#SQ])HE3^I;A-G/ /AW1:#V;<81?Y^G.\ZS3)K;7<^ZM,5
ME/Y'9,M57P9^18QB%S(>8QVLAMO^:$CM=0I*%+;2DQA:=9U2V8C$
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MR5454]OJ1FD8VG2!9%BE(
M
M
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MN7
M
M                                      CS?<L[RL-8^OR!K:FF.1;#
MD!M[$\)M29?5'>7AF+1+385YVJ;<0ZMMZ[QNIBO(Z&VXQ*6E?T/M5G2.(K\A
M:@ ;!?5GQ;K>8O.[C_I')87S\#GY0_F&R8JEN-,3< U_63,QR*EDO,.-2F&<
MJ9IT4Y.,J)UM=@E233T[DQ:=(U%HW'CQX<=B)$89BQ8K+4>-&CM(8CQX["$M
M,L,,M)2VRRRVDDI2DB2E)$1%T%"7F          %?S]S7L6NS'V*4F)5LSS*
MU+QXUSAU[#3)\S<+(KS(,YV0LUL=B"B29.,YO5*4GJHUMI;5UZ&24VTY(E'?
M&8 )[WVO>%SJ#@5LS+)S;S2,\Y+YA+J261DQ(I<>P'6U"F8R:FD&I:[V/8,K
M,E+1^X21=%$HA5?FF$D@8       /BY)D=#AV.W^793;0:'&,6I;7(\CO;-]
M$6MI:&C@OV=O;6$IPR;C0:ZOBN/.N*^B&T&9_0@%7)[)^:5_SSY<[*WQ.<G1
M\.<EEA^HL?G=$N8QJG&I$MK%H*V"ZE'L;A4F1;V".YPDV=E()"C;)!%?$:0A
M@<)']MMN/.-M--K===6EMIIM*EN..+424-MH21J6M:C(B(BZF8"S,]-_!T^"
M_"G!<.R:H*MW)LU2-J[I-YI*;"!E>10HQ5>&25F2G&RP+&V8M<ZR2ULE9(F/
M-]"D*ZTVG64MJXQ
M
M
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M-ITJ+,X4I
M
M                                             1!/NPK.8UC_  8I
MD,]U?/N.1=G)D='?W4RIA:3BP6>XE>$O.S=2%=%$:C\?X3(B5ULQ^*)0U!8
M#?)]N!DE51^SO"ZNQ^#\S,M2[=QNA^61G(*UBX^SE[WY89*3VSOR/%9O<?0_
MZF\I=/KU+&_PBQ"%*0        !U!O[>>NN-.FMB;VVO<HHL!UGC4[)+Z7U:
M.7*3'2EJOI:AAYUA,Z_R&T>9@U\8EI5)FR&FB/JLA,1K.@JJ>3&^<LY/[_V]
MR"S<^S(]LYU>YA*@I>5(8I(-A+4FBQF"^M*''*S%J%J-6Q367?\ &BH[C-74
MSNB-(T0Z.$C^VVW'G&VFFUNNNK2VTTVE2W''%J)*&VT)(U+6M1D1$1=3,!:?
M>M7C=(XE\&>-^C+2"5?E.,Z]A7.>Q3;2EZ/L/.9<O.<Y@ON]J7))U&39%)A-
MN+(E&Q&;+HDB))43.LZI9RB       $7_P"Y4YY?PCTA0<+-?W/Q]@[_ (;&
M2;0<AN=LNCTI66CS4:J6XA2'HKVQLKJ51S-)F3E963F'4]DE)GG2..J$%D6@
M WO?;_\ !17++F/6[4S&J3+TUQ;D4>Q\D1+CFY!R/8:Y,EW5N(GWD;#[2;NK
M<N9C:TN-.1*E4=U)%*08QO.D:>(L2!2D
M
M
M
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MHEMLSNT_PO'UKO/#0A-P%:0
M
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MG9V45U>=K3MRV2[)-;AD"+&IHJTGV.MP3?Z$MY?6FTZRELA&(
M
M
M
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M%2I9_7"J#"J*)(=0EPFT_3/WTMFI!FK\?:9$2R.S&B4+(6#E>#8+F>S<OQ[
M-=XK?YOF^663%/C6*8O5S+J_O+.29^&%6UD!I^7*>-*349)29)0E2E=$I,R"
MRS]0? Z5Z_\ A[C>M,L*"]M_.[>3L[<<B \S,BPLNO(%?!AXG"L&D$4N#AN/
MUD6$I:%N,.STRGV5&V\0IM.LI;2!B
M
M
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MLFQO%8:K')\AH\<KT(?<5.OK:!3PTMQFC?DN*DV$B.P2(["36LS5T0@NI]"
M86[=]GOKXT9'F.['Y>Z/A28"G43:/%\RA;(RN,MDU)<;=P[6Q9;E:74K0:>W
MX?<:B,B+K]!/EF1HSY4?=':@QF+94'#_ $KD6SLA)#K$38.X37A6 Q))&9LV
M$+#:6;*S;+*]:2(E,R96-/D9F?=T27?G%)\4:HI?+?G1R@YP9DG,.16T+G,$
M0),M_&<.C*_)]>X2W+)*'6,1PV"I%15K7':;:=EJ0[82D-H^3(>4DE#.(B.0
MQ'$@ RXX5<*MW<[]W4FD])TGR)LCQV689A9-R$8EKG$D2&V;#+,LL&6U_'A1
M^_LCQT=TF?)4AAA"W%D0B9B(UD6:/#WB;JGA-H#"./>GZ];&.8G&<DVU[-;8
M+(,XRZQ)MW(\WRB2PA"9=Y>RVR^A?NHL5MF(P2(T=EM%,SK.J63H@      !
M#U^YMYZFRQB7 '75YVN2/R79O(9ROE+):8Y$FQUGK>R0TKL-$A9HR2;'<+N+
MQU#J#Z*61V4CQ1*'&+  2&_MU>#*>2/+-[D+G-$F?J;BT==DT(K"(3M9D&Z+
M$W5Z]K$$\@FI)X>F,]D#JFU*7%EPZ\G$]DDNN%YTC06!8J2
M
M
M
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M54L2_>KY%NRPG&,AHVWTS7JJ.I1O$X:?&7:9=3ZS$S'(8N_YD#U7?XH&'?\
MXY[7_P#GX3YK>T9>Z X7\4>+!2G./>@-8ZJL)\1,"QR#&<9A(RVS@(4E:8%G
MF,Y,S*K*"EQ)+)E^8XV2^JNWN,S.)F9YC)P0
M
M
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M!IU-L4]>\:4+75UD;N(E=11:=9U2SO$
M
M
M
M
M
M
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MHVQLQQV:A,[%ZO$F'U+J84QIFQD6IMRU(CLPV?FUWMX0)E0K2
M
M
M
M
M
M
M                         ZCWM_U4YA_U1_\ NQ7_ %[?]5/\]/\ SP__
M *9_L_[?03 A7<K?X/?G>0?Q+_U;?M_,K'N_@M_?U?J7L[IO3\Y_O2?WWY]X
M>[Y?;^\^9^W][V"R/V4--.T/X">6?^E/[QSL\,CX_P#"_P#SE/B[_F.^/X'\
M:/W_ )O#T\?ROW?A[>_][W#*-?I_<&/W_P!RO_\ #O\ _P! !Q^D<TPO^%WS
M'OSS^]I\'?#[/UI_?B?#[?*OS>'^'?\ PAV=G3S>3\79T\7XNH<?I&S'0O\
M>S?*A?I__,<?GWF;\O\ 'K_.Y?%[_DS_ (OS?XG?_P!MO#XNO=X?W?C\7R/W
MG01Q^G]P2]/6!V?I6;XO\U!X_!.\?^;1^1^3=GRV>S\\^7_5?F[?_KGE_>?)
MZ=WUZBNW[*6VL8@
(        _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g210381dei0011.jpg
<TEXT>
begin 644 g210381dei0011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !" -H# 2(  A$! Q$!_\0
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MO&7,KBT444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF&ZB^6:WE^]$_;/J/?V-5? _BBY\1V=['J,,4&HV5P89XH@0H]#@DGJ&'X4
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M?0DC^0-=19W=S/902SZ?/#,\:L\7FJ=C$9*]>QXH$:%%%% !1110 4UE###
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
